<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37166702</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1934</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>440</EndPage><MedlinePgn>399-440</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40263-023-01007-6</ELocationID><Abstract><AbstractText>The sigma-1 receptor is a 223 amino acid-long protein with a recently identified structure. The sigma-2 receptor is a genetically unrelated protein with a similarly shaped binding pocket and acts to influence cellular activities similar to the sigma-1 receptor. Both proteins are highly expressed in neuronal tissues. As such, they have become targets for treating neurological diseases, including Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD), multiple sclerosis (MS), Rett syndrome (RS), developmental and epileptic encephalopathies (DEE), and motor neuron disease/amyotrophic lateral sclerosis (MND/ALS). In recent years, there have been many pre-clinical and clinical studies of sigma receptor (1 and 2) ligands for treating neurological disease. Drugs such as blarcamesine, dextromethorphan and pridopidine, which have sigma-1 receptor activity as part of their pharmacological profile, are effective in treating multiple aspects of several neurological diseases. Furthermore, several sigma-2 receptor ligands are under investigation, including CT1812, rivastigmine and SAS0132. This review aims to provide a current and up-to-date analysis of the current clinical and pre-clinical data of drugs with sigma receptor activities for treating neurological disease.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Malar</LastName><ForeName>Dicson S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0003-4253-9496</Identifier><AffiliationInfo><Affiliation>Natural Products for Neuroprotection and Anti-ageing Research Unit, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Thitilertdecha</LastName><ForeName>Premrutai</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1853-4073</Identifier><AffiliationInfo><Affiliation>Siriraj Research Group in Immunobiology and Therapeutic Sciences, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruckvongacheep</LastName><ForeName>Kanokphorn S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0009-0006-3656-2269</Identifier><AffiliationInfo><Affiliation>Department of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brimson</LastName><ForeName>Sirikalaya</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3593-2601</Identifier><AffiliationInfo><Affiliation>Department of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tencomnao</LastName><ForeName>Tewin</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4177-2165</Identifier><AffiliationInfo><Affiliation>Natural Products for Neuroprotection and Anti-ageing Research Unit, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brimson</LastName><ForeName>James M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-2074-8262</Identifier><AffiliationInfo><Affiliation>Natural Products for Neuroprotection and Anti-ageing Research Unit, Chulalongkorn University, Bangkok, Thailand. jamesmichael.b@chula.ac.th.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research, Innovation and International Affairs, Faculty of Allied Health Sciences, Chulalongkorn University, Room 409, ChulaPat-1 Building, 154 Rama 1 Road, Bangkok, 10330, Thailand. jamesmichael.b@chula.ac.th.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="Y">Receptors, sigma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065886" MajorTopicYN="Y">Neurodevelopmental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37166702</ArticleId><ArticleId IdType="pmc">PMC10173947</ArticleId><ArticleId IdType="doi">10.1007/s40263-023-01007-6</ArticleId><ArticleId IdType="pii">10.1007/s40263-023-01007-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA. 1996;93(15):8072&#x2013;8077. doi: 10.1073/pnas.93.15.8072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.15.8072</ArticleId><ArticleId IdType="pmc">PMC38877</ArticleId><ArticleId IdType="pubmed">8755605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su TP. &#x3c3;-1 Receptors (&#x3c3;1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther. 2003;306(2):718&#x2013;725. doi: 10.1124/jpet.103.051284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.103.051284</ArticleId><ArticleId IdType="pubmed">12730355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su TP. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci USA. 2001;98(2):491&#x2013;496. doi: 10.1073/pnas.021413698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.021413698</ArticleId><ArticleId IdType="pmc">PMC14614</ArticleId><ArticleId IdType="pubmed">11149946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita M, Matsuoka Y, Suzuki T, Mirrielees J, Yang J. Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands. Brain Res. 2012;1452:1&#x2013;9. doi: 10.1016/j.brainres.2012.02.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.02.070</ArticleId><ArticleId IdType="pmc">PMC3670091</ArticleId><ArticleId IdType="pubmed">22433979</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM, Akula KK, Abbas H, Ferry DR, Kulkarni SK, Russell ST, et al. Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression. Sci Rep. 2020;10(1):9251. doi: 10.1038/s41598-020-65849-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-65849-6</ArticleId><ArticleId IdType="pmc">PMC7280195</ArticleId><ArticleId IdType="pubmed">32514120</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM, Brown CA, Safrany ST. Antagonists show GTP-sensitive high-affinity binding to the sigma-1 receptor. Br J Pharmacol. 2011;164(2B):772&#x2013;780. doi: 10.1111/j.1476-5381.2011.01417.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01417.x</ArticleId><ArticleId IdType="pmc">PMC3188898</ArticleId><ArticleId IdType="pubmed">21486275</ArticleId></ArticleIdList></Reference><Reference><Citation>Natsvlishvili N, Goguadze N, Zhuravliova E, Mikeladze D. Sigma-1 receptor directly interacts with Rac1-GTPase in the brain mitochondria. BMC Biochem. 2015;16(1):1&#x2013;7. doi: 10.1186/s12858-015-0040-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12858-015-0040-y</ArticleId><ArticleId IdType="pmc">PMC4430930</ArticleId><ArticleId IdType="pubmed">25924612</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323(5916):934&#x2013;937. doi: 10.1126/science.1166127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166127</ArticleId><ArticleId IdType="pmc">PMC2947205</ArticleId><ArticleId IdType="pubmed">19213917</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs. 2004;18(5):269&#x2013;284. doi: 10.2165/00023210-200418050-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00023210-200418050-00001</ArticleId><ArticleId IdType="pubmed">15089113</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruoho AE, Chu UB, Ramachandran S, Fontanilla D, Mavlyutov T, Hajipour AR. The ligand binding region of the sigma-1 receptor: studies utilizing photoaffinity probes, sphingosine and N-alkylamines. Curr Pharm Des. 2012;18(7):920&#x2013;929. doi: 10.2174/138161212799436584.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799436584</ArticleId><ArticleId IdType="pmc">PMC4440231</ArticleId><ArticleId IdType="pubmed">22288412</ArticleId></ArticleIdList></Reference><Reference><Citation>Vavers E, Zvejniece L, Maurice T, Dambrova M. Allosteric modulators of sigma-1 receptor: a review. Front Pharmacol. 2019;10:223. doi: 10.3389/fphar.2019.00223.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00223</ArticleId><ArticleId IdType="pmc">PMC6433746</ArticleId><ArticleId IdType="pubmed">30941035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su TP. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol. 2005;3(4):267&#x2013;280. doi: 10.2174/157015905774322516.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157015905774322516</ArticleId><ArticleId IdType="pmc">PMC2268997</ArticleId><ArticleId IdType="pubmed">18369400</ArticleId></ArticleIdList></Reference><Reference><Citation>Quirion R, Chicheportiche R, Contreras PC, Johnson KM, Lodge D, Tam SW, et al. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci. 1987;10(11):444&#x2013;446. doi: 10.1016/0166-2236(87)90094-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-2236(87)90094-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MVL, O&#x2019;Neill M, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64(14):4875&#x2013;4886. doi: 10.1158/0008-5472.CAN-03-3180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-03-3180</ArticleId><ArticleId IdType="pubmed">15256458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Prescott AR, Spruce BA, Sanderson J, Duncan G. Sigma receptor antagonists inhibit human lens cell growth and induce pigmentation. Invest Ophthalmol Vis Sci. 2005;46(4):1403&#x2013;1408. doi: 10.1167/iovs.04-1209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.04-1209</ArticleId><ArticleId IdType="pubmed">15790908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131(3):596&#x2013;610. doi: 10.1016/j.cell.2007.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.08.036</ArticleId><ArticleId IdType="pubmed">17981125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of &#x3c3;1 and &#x3c3;2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol. 1994;268(1):9&#x2013;18. doi: 10.1016/0922-4106(94)90115-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0922-4106(94)90115-5</ArticleId><ArticleId IdType="pubmed">7925616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe SA, Jr, Culp SG, De Souza EB. &#x3c3;-Receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology. 1989;124(3):1160&#x2013;1172. doi: 10.1210/endo-124-3-1160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo-124-3-1160</ArticleId><ArticleId IdType="pubmed">2537173</ArticleId></ArticleIdList></Reference><Reference><Citation>Borde P, Cosgrove N, Charmsaz S, Safrany ST, Young L. An investigation of Sigma-1 receptor expression and ligand-induced endoplasmic reticulum stress in breast cancer. Cancer Gene Ther. 2023;30(2):368&#x2013;374. doi: 10.1038/s41417-022-00552-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-022-00552-4</ArticleId><ArticleId IdType="pubmed">36352093</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YS, Lu HL, Zhang LJ, Wu Z. Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy. Med Res Rev. 2014;34(3):532&#x2013;566. doi: 10.1002/med.21297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21297</ArticleId><ArticleId IdType="pubmed">23922215</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson H, Mesangeau C, McCurdy CR, Bowen WD. Sigma-2 receptors play a role in cellular metabolism: stimulation of glycolytic hallmarks by CM764 in human SK-N-SH neuroblastoma. J Pharmacol Exp Ther. 2016;356(2):232&#x2013;243. doi: 10.1124/jpet.115.228387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.115.228387</ArticleId><ArticleId IdType="pmc">PMC4746495</ArticleId><ArticleId IdType="pubmed">26574517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux CG, Greene SF. Sigma receptors [&#x3c3;Rs]: biology in normal and diseased states. J Recept Signal Transduct Res. 2016;36(4):327&#x2013;388. doi: 10.3109/10799893.2015.1015737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10799893.2015.1015737</ArticleId><ArticleId IdType="pmc">PMC4906365</ArticleId><ArticleId IdType="pubmed">26056947</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Yu CF, Wang SC, Li HY, Lin CM, Wang HH, et al. Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor. BMC Cancer. 2019;19(1):473. doi: 10.1186/s12885-019-5700-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-019-5700-7</ArticleId><ArticleId IdType="pmc">PMC6528305</ArticleId><ArticleId IdType="pubmed">31109310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K, Wang C, Sun T. The roles of intracellular chaperone proteins, sigma receptors, in Parkinson's disease (PD) and major depressive disorder (MDD) Front Pharmacol. 2019;10:528. doi: 10.3389/fphar.2019.00528.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00528</ArticleId><ArticleId IdType="pmc">PMC6537631</ArticleId><ArticleId IdType="pubmed">31178723</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiadis MO, Karoutzou O, Foscolos AS, Papanastasiou I. Sigma receptor (&#x3c3;R) ligands with antiproliferative and anticancer activity. Molecules. 2017;22:9. doi: 10.3390/molecules22091408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22091408</ArticleId><ArticleId IdType="pmc">PMC6151391</ArticleId><ArticleId IdType="pubmed">28841173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebreselassie D, Bowen WD. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur J Pharmacol. 2004;493(1&#x2013;3):19&#x2013;28. doi: 10.1016/j.ejphar.2004.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2004.04.005</ArticleId><ArticleId IdType="pubmed">15189760</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro S. Lipid rafts: elusive or illusive? Cell. 2003;115(4):377&#x2013;388. doi: 10.1016/S0092-8674(03)00882-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00882-1</ArticleId><ArticleId IdType="pubmed">14622593</ArticleId></ArticleIdList></Reference><Reference><Citation>Alon A, Lyu J, Braz JM, Tummino TA, Craik V, O&#x2019;Meara MJ, et al. Structures of the &#x3c3;2 receptor enable docking for bioactive ligand discovery. Nature. 2021;600(7890):759&#x2013;764. doi: 10.1038/s41586-021-04175-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04175-x</ArticleId><ArticleId IdType="pmc">PMC8867396</ArticleId><ArticleId IdType="pubmed">34880501</ArticleId></ArticleIdList></Reference><Reference><Citation>Terada K, Migita K, Matsushima Y, Kamei C. Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders. Neural Regen Res. 2019;14(11):1893&#x2013;1894. doi: 10.4103/1673-5374.259609.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.259609</ArticleId><ArticleId IdType="pmc">PMC6676876</ArticleId><ArticleId IdType="pubmed">31290438</ArticleId></ArticleIdList></Reference><Reference><Citation>Abate C, Niso M, Berardi F. Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations. Future Med Chem. 2018;10(16):1997&#x2013;2018. doi: 10.4155/fmc-2018-0072.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc-2018-0072</ArticleId><ArticleId IdType="pubmed">29966437</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantonero C, Camello PJ, Abate C, Berardi F, Salido GM, Rosado JA, et al. NO1, a new Sigma 2 receptor/TMEM97 fluorescent ligand, downregulates SOCE and promotes apoptosis in the triple negative breast cancer cell lines. Cancers (Basel). 2020;12(2):257. doi: 10.3390/cancers12020257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12020257</ArticleId><ArticleId IdType="pmc">PMC7072710</ArticleId><ArticleId IdType="pubmed">31973006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C, Vangveravong S, McDunn JE, Hawkins WG, Mach RH. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer. Br J Cancer. 2013;109(9):2368&#x2013;2377. doi: 10.1038/bjc.2013.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2013.593</ArticleId><ArticleId IdType="pmc">PMC3817331</ArticleId><ArticleId IdType="pubmed">24104966</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C, Riad A, Mach RH. The biological function of Sigma-2 receptor/TMEM97 and its utility in PET imaging studies in cancer. Cancers (Basel). 2020;12(7):1877. doi: 10.3390/cancers12071877.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12071877</ArticleId><ArticleId IdType="pmc">PMC7409002</ArticleId><ArticleId IdType="pubmed">32668577</ArticleId></ArticleIdList></Reference><Reference><Citation>2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327&#x2013;406. 10.1002/alz.12328.</Citation><ArticleIdList><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329&#x2013;344. doi: 10.1056/NEJMra0909142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0909142</ArticleId><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol. 2011;68(8):1062&#x2013;1064. doi: 10.1001/archneurol.2011.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.70</ArticleId><ArticleId IdType="pubmed">21482918</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria Lopez JA, Gonz&#xe1;lez HM, L&#xe9;ger GC. Alzheimer's disease. Handb Clin Neurol. 2019;167:231&#x2013;255. doi: 10.1016/b978-0-12-804766-8.00013-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-804766-8.00013-3</ArticleId><ArticleId IdType="pubmed">31753135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Caraci F, Cuello AC, Caruso G, Nistic&#xf2; R, Corbo M, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease. Front Immunol. 2020;11:456. doi: 10.3389/fimmu.2020.00456.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00456</ArticleId><ArticleId IdType="pmc">PMC7137904</ArticleId><ArticleId IdType="pubmed">32296418</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, et al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26(5):769&#x2013;780. doi: 10.1038/s41591-020-0815-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0815-6</ArticleId><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Fern&#xe1;ndez C, Entrena JM, Baeyens JM, Cobos EJ. Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics. Adv Exp Med Biol. 2017;964:109&#x2013;132. doi: 10.1007/978-3-319-50174-1_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-50174-1_9</ArticleId><ArticleId IdType="pubmed">28315268</ArticleId></ArticleIdList></Reference><Reference><Citation>Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem. 2003;10(20):2073&#x2013;2080. doi: 10.2174/0929867033456783.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867033456783</ArticleId><ArticleId IdType="pubmed">12871086</ArticleId></ArticleIdList></Reference><Reference><Citation>De B, Nadal X, Portillo-salido E, S&#xe1;nchez-arroyos R, Ovalle S, Palacios G, et al. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain. 2009;145(3):294&#x2013;303. doi: 10.1016/j.pain.2009.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2009.05.013</ArticleId><ArticleId IdType="pubmed">19505761</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto FR, Cend&#xe1;n CM, S&#xe1;nchez-Fern&#xe1;ndez C, Cobos EJ, Entrena JM, Tejada MA, et al. Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice. J Pain. 2012;13(11):1107&#x2013;1121. doi: 10.1016/j.jpain.2012.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2012.08.006</ArticleId><ArticleId IdType="pubmed">23063344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanillo D, Romero L, Merlos M, Vela JM. Sigma 1 receptor: a new therapeutic target for pain. Eur J Pharmacol. 2013;716(1&#x2013;3):78&#x2013;93. doi: 10.1016/j.ejphar.2013.01.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2013.01.068</ArticleId><ArticleId IdType="pubmed">23500210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T, et al. An increase of sigma1 receptors in the aged monkey brain. Neurobiol Aging. 2003;24(5):745&#x2013;752. doi: 10.1016/S0197-4580(02)00152-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00152-5</ArticleId><ArticleId IdType="pubmed">12885582</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DR, Mactutus CF, Booze RM. Sigma binding sites identified by [3H] DTG are elevated in aged Fischer-344&#xd7; Brown Norway (F1) rats. Synapse. 2000;35(4):311&#x2013;313. doi: 10.1002/(SICI)1098-2396(20000315)35:4&lt;311::AID-SYN9&gt;3.0.CO;2-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-2396(20000315)35:4&lt;311::AID-SYN9&gt;3.0.CO;2-5</ArticleId><ArticleId IdType="pubmed">10657041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiwata K, Kobayashi T, Kawamura K, Matsuno K. Age-related changes of the binding of [3H] SA4503 to sigma1 receptors in the rat brain. Ann Nucl Med. 2003;17(1):73&#x2013;77. doi: 10.1007/BF02988264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02988264</ArticleId><ArticleId IdType="pubmed">12691135</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsager J, Fedorova TD, Berge NV, Klinge MW, Knudsen K, Hansen AK, et al. Cardiac 11C-donepezil binding increases with age in healthy humans: potentially signifying Sigma-1 receptor upregulation. J Cardiovasc Pharmacol Ther. 2019;24(4):365&#x2013;370. doi: 10.1177/1074248419838509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248419838509</ArticleId><ArticleId IdType="pubmed">30913922</ArticleId></ArticleIdList></Reference><Reference><Citation>Norbury R, Travis MJ, Erlandsson K, Waddington W, Owens J, Pimlott S, et al. In vivo imaging of muscarinic receptors in the aging female brain with (R, R)[123I]-I-QNB and single photon emission tomography. Exp Gerontol. 2005;40(3):137&#x2013;145. doi: 10.1016/j.exger.2004.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2004.10.002</ArticleId><ArticleId IdType="pubmed">15763390</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Mintun MA, Moerlein SM, Snyder AZ. Greater loss of 5-HT2A receptors in midlife than in late life. Am J Psychiatry. 2002;159(3):430&#x2013;435. doi: 10.1176/appi.ajp.159.3.430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.159.3.430</ArticleId><ArticleId IdType="pubmed">11870007</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue M, Suhara T, Sudo Y, Okubo Y, Yasuno F, Kishimoto T, et al. Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci. 2001;69(9):1079&#x2013;1084. doi: 10.1016/s0024-3205(01)01205-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0024-3205(01)01205-x</ArticleId><ArticleId IdType="pubmed">11508650</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM, Brimson S, Chomchoei C, Tencomnao T. Using Sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets. 2020;24(10):1009&#x2013;1028. doi: 10.1080/14728222.2020.1805435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1805435</ArticleId><ArticleId IdType="pubmed">32746649</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasanth MI, Malar D, Tencomnao T, Brimson J. The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer&#x2019;s Disease. Expert Opin Ther Targets. 2021;25(5):401&#x2013;414. doi: 10.1080/14728222.2021.1939681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2021.1939681</ArticleId><ArticleId IdType="pubmed">34110944</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, Oda K, et al. Low density of sigma 1 receptors in early Alzheimer&#x2019;s disease. Ann Nucl Med. 2008;22(3):151&#x2013;156. doi: 10.1007/s12149-007-0094-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12149-007-0094-z</ArticleId><ArticleId IdType="pubmed">18498028</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42(1):85&#x2013;94. doi: 10.1002/ana.410420114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420114</ArticleId><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida N, Ujike H, Tanaka Y, Sakai A, Yamamoto M, Fujisawa Y, et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(12):1062&#x2013;1066. doi: 10.1176/appi.ajgp.13.12.1062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajgp.13.12.1062</ArticleId><ArticleId IdType="pubmed">16319298</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruszak A, Safranow K, Gacia M, Gabryelewicz T, S&#x142;owik A, Styczy&#x144;ska M, et al. Sigma receptor type 1 gene variation in a group of polish patients with Alzheimer&#x2019;s disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23(6):432&#x2013;438. doi: 10.1159/000101990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000101990</ArticleId><ArticleId IdType="pubmed">17457031</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Zheng L, Halliday G, Dobson-Stone C, Wang Y, Tang H-D, et al. Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease. Curr Alzheimer Res. 2011;8(7):765&#x2013;770. doi: 10.2174/156720511797633232.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511797633232</ArticleId><ArticleId IdType="pubmed">21605063</ArticleId></ArticleIdList></Reference><Reference><Citation>Feher A, Juhasz A, Laszlo A, Kalman J, Jr, Pakaski M, Kalman J, et al. Association between a variant of the sigma-1 receptor gene and Alzheimer's disease. Neurosci Lett. 2012;517(2):136&#x2013;139. doi: 10.1016/j.neulet.2012.04.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2012.04.046</ArticleId><ArticleId IdType="pubmed">22561649</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin JL, Fang M, Zhao YX, Liu XY. Roles of sigma-1 receptors in Alzheimer&#x2019;s disease. Int J Clin Exp Med. 2015;8(4):4808&#x2013;4820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484039</ArticleId><ArticleId IdType="pubmed">26131055</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai SY, Hayashi T, Harvey BK, Wang Y, Wu WW, Shen RF, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1&#x2022;GTP pathway. Proc Natl Acad Sci USA. 2009;106(52):22468&#x2013;22473. doi: 10.1073/pnas.0909089106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909089106</ArticleId><ArticleId IdType="pmc">PMC2792161</ArticleId><ArticleId IdType="pubmed">20018732</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, et al. AF710B, a novel M1/&#x3c3;1 agonist with therapeutic efficacy in animal models of Alzheimer's disease. Neurodegener Dis. 2016;16(1&#x2013;2):95&#x2013;110. doi: 10.1159/000440864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000440864</ArticleId><ArticleId IdType="pmc">PMC4803577</ArticleId><ArticleId IdType="pubmed">26606130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, et al. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. Neurobiol Dis. 2019;124:489&#x2013;504. doi: 10.1016/j.nbd.2018.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.12.022</ArticleId><ArticleId IdType="pmc">PMC6363865</ArticleId><ArticleId IdType="pubmed">30594810</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai SYA, Pokrass MJ, Klauer NR, Nohara H, Su TP. Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid. Proc Natl Acad Sci USA. 2015;112(21):6742&#x2013;6747. doi: 10.1073/pnas.1422001112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1422001112</ArticleId><ArticleId IdType="pmc">PMC4450430</ArticleId><ArticleId IdType="pubmed">25964330</ArticleId></ArticleIdList></Reference><Reference><Citation>Christ MG, Huesmann H, Nagel H, Kern A, Behl C. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. Cells. 2019;8(3):211. doi: 10.3390/cells8030211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8030211</ArticleId><ArticleId IdType="pmc">PMC6468724</ArticleId><ArticleId IdType="pubmed">30832324</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo MA, Faggioni A, Cirone M. Could autophagy dysregulation link neurotropic viruses to Alzheimer&#x2019;s disease? Neural Regen Res. 2019;14(9):1503&#x2013;1506. doi: 10.4103/1673-5374.253508.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.253508</ArticleId><ArticleId IdType="pmc">PMC6557098</ArticleId><ArticleId IdType="pubmed">31089040</ArticleId></ArticleIdList></Reference><Reference><Citation>McBrayer M, Nixon RA. Lysosome and calcium dysregulation in Alzheimer's disease: partners in crime. Biochem Soc Trans. 2013;41(6):1495&#x2013;1502. doi: 10.1042/BST20130201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20130201</ArticleId><ArticleId IdType="pmc">PMC3960943</ArticleId><ArticleId IdType="pubmed">24256243</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin MS, Stachowiak A, Mamun AA, Tzvetkov NT, Takeda S, Atanasov AG, et al. Autophagy and Alzheimer&#x2019;s disease: from molecular mechanisms to therapeutic implications. Front Aging Neurosci. 2018;10:04. doi: 10.3389/fnagi.2018.00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00004</ArticleId><ArticleId IdType="pmc">PMC5797541</ArticleId><ArticleId IdType="pubmed">29441009</ArticleId></ArticleIdList></Reference><Reference><Citation>Callens M, Loncke J, Bultynck G. Dysregulated Ca2+ homeostasis as a central theme in neurodegeneration: lessons from Alzheimer&#x2019;s disease and Wolfram syndrome. Cells. 2022;11(12):1963. doi: 10.3390/cells11121963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11121963</ArticleId><ArticleId IdType="pmc">PMC9221778</ArticleId><ArticleId IdType="pubmed">35741091</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of A&#x3b2;42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216&#x2013;223. doi: 10.1016/S0140-6736(08)61075-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)61075-2</ArticleId><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 2023;388(1):9&#x2013;21. doi: 10.1056/NEJMoa2212948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2212948</ArticleId><ArticleId IdType="pubmed">36449413</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27(4):796&#x2013;807. doi: 10.1523/JNEUROSCI.3501-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3501-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannuzzo M. On the physiological/pathological link between A&#x3b2; peptide, cholesterol, calcium ions and membrane deformation: a molecular dynamics study. Biochim Biophys Acta. 2016;1858(6):1380&#x2013;1389. doi: 10.1016/j.bbamem.2016.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2016.03.018</ArticleId><ArticleId IdType="pubmed">27003127</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature. 1995;373(6514):523&#x2013;527. doi: 10.1038/373523a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/373523a0</ArticleId><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM. The Pharmacology of the Sigma-1 Receptor [Doctoral Thesis]. In: The University of Bath online repository. 2010. http://opus.bath.ac.uk/19712/. Accessed 1 Dec 2022.</Citation></Reference><Reference><Citation>Katnik C, Guerrero WR, Pennypacker KR, Herrera Y, Cuevas J. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J Pharmacol Exp Ther. 2006;319(3):1355&#x2013;1365. doi: 10.1124/jpet.106.107557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.106.107557</ArticleId><ArticleId IdType="pubmed">16988055</ArticleId></ArticleIdList></Reference><Reference><Citation>Delprat B, Crouzier L, Su TP, Maurice T. At the crossing of ER stress and MAMs: a key role of sigma-1 receptor? Adv Exp Med Biol. 2020;1131:699&#x2013;718. doi: 10.1007/978-3-030-12457-1_2878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-12457-1_2878</ArticleId><ArticleId IdType="pubmed">31646531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. Trends Cell Biol. 2009;19(2):81&#x2013;88. doi: 10.1016/j.tcb.2008.12.00279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2008.12.00279</ArticleId><ArticleId IdType="pmc">PMC2750097</ArticleId><ArticleId IdType="pubmed">19144519</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512&#x2013;521. doi: 10.1111/epi.13709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.13709</ArticleId><ArticleId IdType="pmc">PMC5386840</ArticleId><ArticleId IdType="pubmed">28276062</ArticleId></ArticleIdList></Reference><Reference><Citation>Specchio N, Curatolo P. Developmental and epileptic encephalopathies: what we do and do not know. Brain. 2021;144(1):32&#x2013;43. doi: 10.1093/brain/awaa371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa371</ArticleId><ArticleId IdType="pubmed">33279965</ArticleId></ArticleIdList></Reference><Reference><Citation>Raga S, Specchio N, Rheims S, Wilmshurst JM. Developmental and epileptic encephalopathies: recognition and approaches to care. Epileptic Disord. 2021;23(1):40&#x2013;52. doi: 10.1684/epd.2021.1244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/epd.2021.1244</ArticleId><ArticleId IdType="pubmed">33632673</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffer IE, Liao J. Deciphering the concepts behind &#x201c;Epileptic encephalopathy&#x201d; and &#x201c;Developmental and epileptic encephalopathy&#x201d;. Eur J Paediatr Neurol. 2020;24:11&#x2013;14. doi: 10.1016/j.ejpn.2019.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpn.2019.12.023</ArticleId><ArticleId IdType="pubmed">31926847</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivisano M, Specchio N. What are the epileptic encephalopathies? Curr Opin Neurol. 2020;33(2):179&#x2013;184. doi: 10.1097/wco.0000000000000793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wco.0000000000000793</ArticleId><ArticleId IdType="pubmed">32049741</ArticleId></ArticleIdList></Reference><Reference><Citation>EPX-100 (Clemizole Hydrochloride) as add-on therapy to control convulsive seizures in patients with Dravet syndrome (ARGUS). In: NIH U.S. National Library of Medicine. 2020. https://clinicaltrials.gov/ct2/show/NCT04462770. Accessed 1 Dec 2022.</Citation></Reference><Reference><Citation>Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017;140(3):669&#x2013;683. doi: 10.1093/brain/aww342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww342</ArticleId><ArticleId IdType="pmc">PMC6075536</ArticleId><ArticleId IdType="pubmed">28073790</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasquez A, Buraniqi E, Wirrell EC. New and emerging pharmacologic treatments for developmental and epileptic encephalopathies. Curr Opin Neurol. 2022;35(2):145&#x2013;154. doi: 10.1097/wco.0000000000001029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wco.0000000000001029</ArticleId><ArticleId IdType="pubmed">35102126</ArticleId></ArticleIdList></Reference><Reference><Citation>Miziak B, Czuczwar S. Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome. Expert Opin Drug Discov. 2021;16(5):579&#x2013;593. doi: 10.1080/17460441.2021.1857722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2021.1857722</ArticleId><ArticleId IdType="pubmed">33275464</ArticleId></ArticleIdList></Reference><Reference><Citation>Samanta D. Changing landscape of Dravet syndrome management: an overview. Neuropediatrics. 2020;51(2):135&#x2013;145. doi: 10.1055/s-0040-1701694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1701694</ArticleId><ArticleId IdType="pubmed">32079034</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin P, Reeder T, Sourbron J, de Witte PAM, Gammaitoni AR, Galer BS. An emerging role for Sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci. 2021;22(16):8416. doi: 10.3390/ijms22168416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168416</ArticleId><ArticleId IdType="pmc">PMC8395113</ArticleId><ArticleId IdType="pubmed">34445144</ArticleId></ArticleIdList></Reference><Reference><Citation>Vavers E, Zvejniece B, Stelfa G, Svalbe B, Vilks K, Kupats E, et al. Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures. Neurobiol Dis. 2021;150:105244. doi: 10.1016/j.nbd.2020.105244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105244</ArticleId><ArticleId IdType="pubmed">33385516</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell. 2004;15(1):95&#x2013;105. doi: 10.1016/j.molcel.2004.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2004.06.029</ArticleId><ArticleId IdType="pubmed">15225551</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci. 2010;13(5):567&#x2013;576. doi: 10.1038/nn.2528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2528</ArticleId><ArticleId IdType="pmc">PMC2860687</ArticleId><ArticleId IdType="pubmed">20383138</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011;121(2):493&#x2013;499. doi: 10.1172/JCI45691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI45691</ArticleId><ArticleId IdType="pmc">PMC3026743</ArticleId><ArticleId IdType="pubmed">21285522</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron NS, Wright GEB, Hayden MR. Huntington Disease. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews, University of Washington, Seattle. 1993. https://www.ncbi.nlm.nih.gov/books/NBK1305/.</Citation></Reference><Reference><Citation>Frank S. Treatment of Huntington&#x2019;s disease. Neurotherapeutics. 2014;11(1):153&#x2013;160. doi: 10.1007/s13311-013-0244-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-013-0244-z</ArticleId><ArticleId IdType="pmc">PMC3899480</ArticleId><ArticleId IdType="pubmed">24366610</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki Y, Tanji K, Mori F, Wakabayashi K. Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington&#x2019;s disease. Neurobiol Dis. 2015;74:25&#x2013;31. doi: 10.1016/j.nbd.2014.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.11.005</ArticleId><ArticleId IdType="pubmed">25449906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97:46&#x2013;59. doi: 10.1016/j.nbd.2016.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.10.006</ArticleId><ArticleId IdType="pmc">PMC5214572</ArticleId><ArticleId IdType="pubmed">27818324</ArticleId></ArticleIdList></Reference><Reference><Citation>Jab&#x142;o&#x144;ska M, Grzelakowska K, Wi&#x15b;niewski B, Mazur E, Leis K, Ga&#x142;&#x105;zka P. Pridopidine in the treatment of Huntington&#x2019;s disease. Rev Neurosci. 2020;31(4):441&#x2013;451. doi: 10.1515/revneuro-2019-0085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2019-0085</ArticleId><ArticleId IdType="pubmed">32083454</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, Lucke-Wold BP, Mookerjee SA, Cavendish JZ, Robson MJ, Scandinaro AL, et al. Role of sigma-1 receptors in neurodegenerative diseases. J Pharmacol Sci. 2015;127(1):17&#x2013;29. doi: 10.1016/j.jphs.2014.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2014.12.005</ArticleId><ArticleId IdType="pubmed">25704014</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Machts J, Keute M, Kaufmann J, Schreiber S, Kasper E, Petri S, et al. Longitudinal clinical and neuroanatomical correlates of memory impairment in motor neuron disease. Neuroimage Clin. 2021;29:102545. doi: 10.1016/j.nicl.2020.102545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102545</ArticleId><ArticleId IdType="pmc">PMC7786131</ArticleId><ArticleId IdType="pubmed">33387861</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med. 2017;19(3):267&#x2013;274. doi: 10.1038/gim.2016.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2016.107</ArticleId><ArticleId IdType="pubmed">27537704</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S. Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019;20(11):2818. doi: 10.3390/ijms20112818.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112818</ArticleId><ArticleId IdType="pmc">PMC6600525</ArticleId><ArticleId IdType="pubmed">31185581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585&#x2013;591. doi: 10.1056/nejm199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo YA. Sodium phenylbutyrate and ursodoxicoltaurine: first approval. CNS Drugs. 2022;36(9):1007&#x2013;1013. doi: 10.1007/s40263-022-00945-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-022-00945-x</ArticleId><ArticleId IdType="pubmed">35907175</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern&#xe1;ndez M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1&#x2013;2):5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A catalyze the metabolic activation of the tyrosine kinase inhibitor masitinib. Chem Res Toxicol. 2022;35(9):1467&#x2013;1481. doi: 10.1021/acs.chemrestox.2c00057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.2c00057</ArticleId><ArticleId IdType="pmc">PMC10226528</ArticleId><ArticleId IdType="pubmed">36048877</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanovas A, Salvany S, Lahoz V, Tarabal O, Piedrafita L, Sabater R, et al. Neuregulin 1-ErbB module in C-bouton synapses on somatic motor neurons: molecular compartmentation and response to peripheral nerve injury. Sci Rep. 2017;7:40155. doi: 10.1038/srep40155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep40155</ArticleId><ArticleId IdType="pmc">PMC5220293</ArticleId><ArticleId IdType="pubmed">28065942</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrando-Grabulosa M, Gaja-Capdevila N, Vela JM, Navarro X. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis. Br J Pharmacol. 2021;178(6):1336&#x2013;1352. doi: 10.1111/bph.15224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15224</ArticleId><ArticleId IdType="pubmed">32761823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov TA, Epstein ML, Liu P, Verbny YI, Ziskind-Conhaim L, Ruoho AE. Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N, N&#x2032;-dimethyltryptamine forming enzyme, indole-N-methyl transferase. Neuroscience. 2012;206:60&#x2013;68. doi: 10.1016/j.neuroscience.2011.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.12.040</ArticleId><ArticleId IdType="pmc">PMC3321351</ArticleId><ArticleId IdType="pubmed">22265729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov TA, Epstein ML, Andersen KA, Ziskind-Conhaim L, Ruoho AE. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience. 2010;167(2):247&#x2013;255. doi: 10.1016/j.neuroscience.2010.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.02.022</ArticleId><ArticleId IdType="pmc">PMC2862368</ArticleId><ArticleId IdType="pubmed">20167253</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Ilieva H, Tamada H, Nomura H, Komine O, Endo F, et al. Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR 1-and SOD 1-linked ALS. EMBO Mol Med. 2016;8(12):1421&#x2013;1437. doi: 10.15252/emmm.201606403.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606403</ArticleId><ArticleId IdType="pmc">PMC5167132</ArticleId><ArticleId IdType="pubmed">27821430</ArticleId></ArticleIdList></Reference><Reference><Citation>Couly S, Khalil B, Viguier V, Roussel J, Maurice T, Li&#xe9;vens J-C. Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis. Hum Mol Genet. 2020;29(4):529&#x2013;540. doi: 10.1093/hmg/ddz267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz267</ArticleId><ArticleId IdType="pubmed">31696229</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollrath J, Sechi A, Dreser A, Katona I, Wiemuth D, Vervoorts J, et al. Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances. Cell Death Dis. 2014;5(6):e1290. doi: 10.1038/cddis.2014.243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.243</ArticleId><ArticleId IdType="pmc">PMC4611717</ArticleId><ArticleId IdType="pubmed">24922074</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreser A, Vollrath JT, Sechi A, Johann S, Roos A, Yamoah A, et al. The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins. Cell Death Differ. 2017;24(10):1655&#x2013;1671. doi: 10.1038/cdd.2017.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2017.88</ArticleId><ArticleId IdType="pmc">PMC5596426</ArticleId><ArticleId IdType="pubmed">28622300</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov TA, Epstein ML, Verbny YI, Huerta MS, Zaitoun I, Ziskind-Conhaim L, et al. Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience. 2013;240:129&#x2013;134. doi: 10.1016/j.neuroscience.2013.02.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2013.02.035</ArticleId><ArticleId IdType="pmc">PMC3665351</ArticleId><ArticleId IdType="pubmed">23458708</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol. 2011;70(6):913&#x2013;919. doi: 10.1002/ana.22534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22534</ArticleId><ArticleId IdType="pubmed">21842496</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukunaga K, Shinoda Y, Tagashira H. The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. J Pharmacol Sci. 2015;127(1):36&#x2013;41. doi: 10.1016/j.jphs.2014.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2014.12.012</ArticleId><ArticleId IdType="pubmed">25704016</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30(2):639&#x2013;649. doi: 10.1523/JNEUROSCI.4988-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P-T, Li&#xe9;vens J-C, Wang S-M, Chuang J-Y, Khalil B, Wu H-E, et al. Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS/FTD models. Nat Commun. 2020;11(1):5580. doi: 10.1038/s41467-020-19396-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19396-3</ArticleId><ArticleId IdType="pmc">PMC7642387</ArticleId><ArticleId IdType="pubmed">33149115</ArticleId></ArticleIdList></Reference><Reference><Citation>Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175&#x2013;1189. doi: 10.1093/brain/awp070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp070</ArticleId><ArticleId IdType="pmc">PMC2677799</ArticleId><ArticleId IdType="pubmed">19339255</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765&#x2013;779. doi: 10.1001/jama.2020.26858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.26858</ArticleId><ArticleId IdType="pubmed">33620411</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006;12(4):367&#x2013;368. doi: 10.1191/135248506ms1373ed.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/135248506ms1373ed</ArticleId><ArticleId IdType="pubmed">16900749</ArticleId></ArticleIdList></Reference><Reference><Citation>Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061&#x2013;1067. doi: 10.1093/sleep/33.8.1061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/33.8.1061</ArticleId><ArticleId IdType="pmc">PMC2910465</ArticleId><ArticleId IdType="pubmed">20815187</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898&#x2013;904. doi: 10.1056/nejm200009283431301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm200009283431301</ArticleId><ArticleId IdType="pubmed">11006365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015;8(6):274&#x2013;293. doi: 10.1177/1756285615605429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285615605429</ArticleId><ArticleId IdType="pmc">PMC4643868</ArticleId><ArticleId IdType="pubmed">26600872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387&#x2013;401. doi: 10.1056/NEJMoa0909494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0909494</ArticleId><ArticleId IdType="pubmed">20089952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263&#x2013;1273. doi: 10.1016/s0140-6736(18)30475-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(18)30475-6</ArticleId><ArticleId IdType="pubmed">29576505</ArticleId></ArticleIdList></Reference><Reference><Citation>Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009&#x2013;1020. doi: 10.1016/s1474-4422(19)30239-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(19)30239-x</ArticleId><ArticleId IdType="pubmed">31492651</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268&#x2013;1276. doi: 10.1212/wnl.45.7.1268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.45.7.1268</ArticleId><ArticleId IdType="pubmed">7617181</ArticleId></ArticleIdList></Reference><Reference><Citation>Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247&#x2013;256. doi: 10.1016/s1474-4422(13)70308-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(13)70308-9</ArticleId><ArticleId IdType="pubmed">24461574</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg S&#xf8;rensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416&#x2013;426. doi: 10.1056/NEJMoa0902533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0902533</ArticleId><ArticleId IdType="pubmed">20089960</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios G, Muro A, Verd&#xfa; E, Pumarola M, Vela JM. Immunohistochemical localization of the sigma1 receptor in Schwann cells of rat sciatic nerve. Brain Res. 2004;1007(1&#x2013;2):65&#x2013;70. doi: 10.1016/j.brainres.2004.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.02.013</ArticleId><ArticleId IdType="pubmed">15064136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Su T-P. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci USA. 2004;101(41):14949&#x2013;14954. doi: 10.1073/pnas.0402890101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402890101</ArticleId><ArticleId IdType="pmc">PMC522002</ArticleId><ArticleId IdType="pubmed">15466698</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhemkov V, Geva M, Hayden MR, Bezprozvanny I. Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases. Int J Mol Sci. 2021;22(8):4082. doi: 10.3390/ijms22084082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22084082</ArticleId><ArticleId IdType="pmc">PMC8071319</ArticleId><ArticleId IdType="pubmed">33920913</ArticleId></ArticleIdList></Reference><Reference><Citation>Berghoff SA, Spieth L, Saher G. Local cholesterol metabolism orchestrates remyelination. Trends Neurosci. 2022;45(4):272&#x2013;283. doi: 10.1016/j.tins.2022.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2022.01.001</ArticleId><ArticleId IdType="pubmed">35153084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenche H, Singh M, Smith J, Shen K. Neuronal mitochondrial dysfunction in a cellular model of circadian rhythm disruption is rescued by donepezil. Biochem Biophys Res Commun. 2021;567:56&#x2013;62. doi: 10.1016/j.bbrc.2021.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.06.029</ArticleId><ArticleId IdType="pubmed">34144501</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxombre B, Lee-Chang C, Duhamel A, Toussaint M, Giroux M, Donnier-Mar&#xe9;chal M, et al. High-affinity &#x3c3;1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. Br J Pharmacol. 2015;172(7):1769&#x2013;1782. doi: 10.1111/bph.13037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13037</ArticleId><ArticleId IdType="pmc">PMC4376455</ArticleId><ArticleId IdType="pubmed">25521311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson&#x2019;s disease: recent advancement. Neurosci Bull. 2017;33(5):585&#x2013;597. doi: 10.1007/s12264-017-0183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-017-0183-5</ArticleId><ArticleId IdType="pmc">PMC5636742</ArticleId><ArticleId IdType="pubmed">28936761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, et al. Finding useful biomarkers for Parkinson&#x2019;s disease. Sci Transl Med. 2018;10(454):eaam6003. doi: 10.1126/scitranslmed.aam6003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aam6003</ArticleId><ArticleId IdType="pmc">PMC6097233</ArticleId><ArticleId IdType="pubmed">30111645</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Le W. Biomarkers for Parkinson&#x2019;s disease: how good are they? Neurosci Bull. 2020;36(2):183&#x2013;194. doi: 10.1007/s12264-019-00433-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-019-00433-1</ArticleId><ArticleId IdType="pmc">PMC6977795</ArticleId><ArticleId IdType="pubmed">31646434</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloem BR, Okun MS, Klein C. Parkinson&#x2019;s disease. Lancet. 2021;397(10291):2284&#x2013;2303. doi: 10.1016/s0140-6736(21)00218-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00218-x</ArticleId><ArticleId IdType="pubmed">33848468</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson disease. In: World Health Organization website. 2022. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease. Accessed 1 Dec 2022.</Citation></Reference><Reference><Citation>LeWitt PA. Levodopa therapy for Parkinson&#x2019;s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64&#x2013;72. doi: 10.1002/mds.26082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26082</ArticleId><ArticleId IdType="pubmed">25449210</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson&#x2019;s disease. Mov Disord. 2016;31(11):1602&#x2013;1609. doi: 10.1002/mds.26712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26712</ArticleId><ArticleId IdType="pubmed">27430479</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683&#x2013;1697. doi: 10.1016/S0140-6736(15)00462-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00462-6</ArticleId><ArticleId IdType="pmc">PMC5792067</ArticleId><ArticleId IdType="pubmed">26595642</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Andersen K, Larsen J, Lolk A, Nielsen H, Kragh-S&#xf8;rensen P. Risk of dementia in Parkinson&#x2019;s disease: a community-based, prospective study. Neurology. 2001;56(6):730&#x2013;736. doi: 10.1212/wnl.56.6.730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.56.6.730</ArticleId><ArticleId IdType="pubmed">11274306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, et al. Function of sigma 1 receptors in Parkinson&#x2019;s disease. Acta Neurol Scand. 2005;112(2):103&#x2013;107. doi: 10.1111/j.1600-0404.2005.00432.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2005.00432.x</ArticleId><ArticleId IdType="pubmed">16008536</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J, Wang L, Zhang T, Zhang B, Chen L. Sigma-1 receptor knockout increases &#x3b1;-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra. Neurobiol Aging. 2017;59:171&#x2013;183. doi: 10.1016/j.neurobiolaging.2017.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.08.007</ArticleId><ArticleId IdType="pubmed">28870519</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Roth GS. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid Redox Signal. 2000;2(3):449&#x2013;460. doi: 10.1089/15230860050192224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/15230860050192224</ArticleId><ArticleId IdType="pubmed">11229358</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori T, Hayashi T, Su TP. Compromising &#x3c3;-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-&#x3ba;B/Bcl-2-dependent mechanism: Potential relevance to Parkinson&#x2019;s disease. J Pharmacol Exp Ther. 2012;341(3):663&#x2013;671. doi: 10.1124/jpet.111.190868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.111.190868</ArticleId><ArticleId IdType="pmc">PMC3362887</ArticleId><ArticleId IdType="pubmed">22399814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagnin M, Ozzano M, Bellio N, Fiorentino I, Follo C, Isidoro C. Dopamine induces apoptosis in APPswe-expressing Neuro2A cells following Pepstatin-sensitive proteolysis of APP in acid compartments. Brain Res. 2012;1471:102&#x2013;117. doi: 10.1016/j.brainres.2012.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771396</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM, Safrany ST, Qassam H, Tencomnao T. Dipentylammonium binds to the Sigma-1 receptor and protects against glutamate toxicity, attenuates dopamine toxicity and potentiates neurite outgrowth in various cultured cell lines. Neurotox Res. 2018;34(2):263&#x2013;272. doi: 10.1007/s12640-018-9883-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-018-9883-5</ArticleId><ArticleId IdType="pubmed">29589276</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. doi: 10.1038/nrdp.2017.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.13</ArticleId><ArticleId IdType="pubmed">28332488</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson&#x2019;s disease. Neurology. 1996;47(6 Suppl 3):S161&#x2013;S170. doi: 10.1212/wnl.47.6_suppl_3.161s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.47.6_suppl_3.161s</ArticleId><ArticleId IdType="pubmed">8959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Crist&#xf3;v&#xe3;o AC, Guhathakurta S, Bok E, Je G, Yoo SD, Choi D-H, et al. NADPH oxidase 1 mediates &#x3b1;-synucleinopathy in Parkinson&#x2019;s disease. J Neurosci. 2012;32(42):14465&#x2013;14477. doi: 10.1523/JNEUROSCI.2246-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2246-12.2012</ArticleId><ArticleId IdType="pmc">PMC3501265</ArticleId><ArticleId IdType="pubmed">23077033</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JD, Zhao X, Li Y, Li GR, Liu XL. Damage to dopaminergic neurons by oxidative stress in Parkinson&#x2019;s disease. Int J Mol Med. 2018;41(4):1817&#x2013;1825. doi: 10.3892/ijmm.2018.3406.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2018.3406</ArticleId><ArticleId IdType="pubmed">29393357</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal A, Fontanilla D, Gopalakrishnan A, Chae Y-K, Markley JL, Ruoho AE. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol. 2012;682(1&#x2013;3):12&#x2013;20. doi: 10.1016/j.ejphar.2012.01.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2012.01.030</ArticleId><ArticleId IdType="pmc">PMC3314091</ArticleId><ArticleId IdType="pubmed">22381068</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Shanmugam A, Markand S, Zorrilla E, Ganapathy V, Smith SB. Sigma 1 receptor regulates the oxidative stress response in primary retinal M&#xfc;ller glial cells via NRF2 signaling and system xc&#x2212;, the Na+-independent glutamate&#x2013;cystine exchanger. Free Radic Biol Med. 2015;86:25&#x2013;36. doi: 10.1016/j.freeradbiomed.2015.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.04.009</ArticleId><ArticleId IdType="pmc">PMC4554890</ArticleId><ArticleId IdType="pubmed">25920363</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasanth MI, Tencomnao T, Brimson JM. The Sigma-1 receptors role in neuroprotection: Comment on Nrf2 as a therapeutic target in ischemic stroke. Expert Opin Ther Targets. 2021;25(7):613&#x2013;614. doi: 10.1080/14728222.2021.1948016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2021.1948016</ArticleId><ArticleId IdType="pubmed">34180350</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM, Prasanth MI, Isidoro C, Sukprasansap M, Tencomnao T. Cleistocalyx nervosum var. paniala seed extracts exhibit sigma-1 antagonist sensitive neuroprotective effects in PC12 cells and protect C. elegans from stress via the SKN-1/NRF-2 pathway. Nutr Healthy Aging. 2021;6(2):131&#x2013;146. doi: 10.3233/NHA-200108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NHA-200108</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM, Prasanth MI, Malar DS, Verma K, Plaingam W, Tencomnao T. Bacopa monnieri protects neuronal cell line and Caenorhabditis elegans models of Alzheimer&#x2019;s disease through sigma-1 receptor antagonist sensitive and antioxidant pathways. Nutr Healthy Aging. 2022;7(3):173&#x2013;196. doi: 10.3233/NHA-220161.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NHA-220161</ArticleId></ArticleIdList></Reference><Reference><Citation>Betzer C, Movius AJ, Shi M, Gai W-P, Zhang J, Jensen PH. Identification of synaptosomal proteins binding to monomeric and oligomeric &#x3b1;-synuclein. PLoS ONE. 2015;10(2):e0116473. doi: 10.1371/journal.pone.0116473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116473</ArticleId><ArticleId IdType="pmc">PMC4319895</ArticleId><ArticleId IdType="pubmed">25659148</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JL, Cuervo AM. Autophagy and human disease: emerging themes. Curr Opin Genet Dev. 2014;26:16&#x2013;23. doi: 10.1016/j.gde.2014.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2014.04.003</ArticleId><ArticleId IdType="pmc">PMC4253630</ArticleId><ArticleId IdType="pubmed">24907664</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type &#x3b1;-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008;283(35):23542&#x2013;23556. doi: 10.1074/jbc.M801992200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M801992200</ArticleId><ArticleId IdType="pmc">PMC2527094</ArticleId><ArticleId IdType="pubmed">18566453</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvagnion C. The role of lipids interacting with &#x3b1;-synuclein in the pathogenesis of Parkinson&#x2019;s disease. J Parkinsons Dis. 2017;7(3):433&#x2013;450. doi: 10.3233/JPD-171103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-171103</ArticleId><ArticleId IdType="pubmed">28671142</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvagnion C, Brown JW, Ouberai MM, Flagmeier P, Vendruscolo M, Buell AK, et al. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of &#x3b1;-synuclein. Proc Natl Acad Sci USA. 2016;113(26):7065&#x2013;7070. doi: 10.1073/pnas.1601899113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1601899113</ArticleId><ArticleId IdType="pmc">PMC4932957</ArticleId><ArticleId IdType="pubmed">27298346</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, et al. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci Rep. 2017;7:40699. doi: 10.1038/srep40699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep40699</ArticleId><ArticleId IdType="pmc">PMC5233976</ArticleId><ArticleId IdType="pubmed">28084443</ArticleId></ArticleIdList></Reference><Reference><Citation>Limegrover CS, Yurko R, Izzo NJ, LaBarbera KM, Rehak C, Look G, et al. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson&#x2019;s patient brain-derived &#x3b1;-synuclein. J Neurosci Res. 2021;99(4):1161&#x2013;1176. doi: 10.1002/jnr.24782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24782</ArticleId><ArticleId IdType="pmc">PMC7986605</ArticleId><ArticleId IdType="pubmed">33480104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold WA, Krishnarajy R, Ellaway C, Christodoulou J. Rett syndrome: a genetic update and clinical review focusing on comorbidities. ACS Chem Neurosci. 2018;9(2):167&#x2013;176. doi: 10.1021/acschemneuro.7b00346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00346</ArticleId><ArticleId IdType="pubmed">29185709</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal S, Xiol C, Pascual-Alonso A, O'Callaghan M, Pineda M, Armstrong J. Genetic landscape of Rett syndrome spectrum: improvements and challenges. Int J Mol Sci. 2019;20(16):3925. doi: 10.3390/ijms20163925.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20163925</ArticleId><ArticleId IdType="pmc">PMC6719047</ArticleId><ArticleId IdType="pubmed">31409060</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320(5880):1224&#x2013;1229. doi: 10.1126/science.1153252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153252</ArticleId><ArticleId IdType="pmc">PMC2443785</ArticleId><ArticleId IdType="pubmed">18511691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyst MJ, Bird A. Rett syndrome: a complex disorder with simple roots. Nat Rev Genet. 2015;16(5):261&#x2013;275. doi: 10.1038/nrg3897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3897</ArticleId><ArticleId IdType="pubmed">25732612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriaucionis S, Paterson A, Curtis J, Guy J, Macleod N, Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol. 2006;26(13):5033&#x2013;5042. doi: 10.1128/mcb.01665-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.01665-05</ArticleId><ArticleId IdType="pmc">PMC1489175</ArticleId><ArticleId IdType="pubmed">16782889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G, et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet. 2011;20(6):1182&#x2013;1196. doi: 10.1093/hmg/ddq563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq563</ArticleId><ArticleId IdType="pubmed">21212100</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer A, Qayumi J, Ronnett G. MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively. Mol Cell Neurosci. 2008;37(4):794&#x2013;807. doi: 10.1016/j.mcn.2008.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2008.01.005</ArticleId><ArticleId IdType="pubmed">18295506</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonzo M, Sirico F, Corrado B. Evidence-based physical therapy for individuals with Rett syndrome: a systematic review. Brain Sci. 2020;10(7):410. doi: 10.3390/brainsci10070410.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10070410</ArticleId><ArticleId IdType="pmc">PMC7407501</ArticleId><ArticleId IdType="pubmed">32630125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehinger Y, Matagne V, Villard L, Roux JC. Rett syndrome from bench to bedside: recent advances. F1000Res. 2018;7:398. doi: 10.12688/f1000research.14056.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.14056.1</ArticleId><ArticleId IdType="pmc">PMC5871944</ArticleId><ArticleId IdType="pubmed">29636907</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahil G, Bollu PC. Rett Syndrome. In: Aboubakr S, Abu-Ghosh A, Acharya A, Adibi Sedeh P, Aeby T, Aeddula N, Et al. Editors. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023. https://www.ncbi.nlm.nih.gov/books/NBK482252/.</Citation><ArticleIdList><ArticleId IdType="pubmed">29489169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno K, Saito Y, Ueda R, Togawa M, Ohmae T, Matsuda E, et al. Effect of serotonin 1A agonists and selective serotonin reuptake inhibitors on behavioral and nighttime respiratory symptoms in Rett syndrome. Pediatr Neurol. 2016;60:54&#x2013;9.e1. doi: 10.1016/j.pediatrneurol.2016.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2016.03.016</ArticleId><ArticleId IdType="pubmed">27212420</ArticleId></ArticleIdList></Reference><Reference><Citation>Neul JL, Lane JB, Lee H-S, Geerts S, Barrish JO, Annese F, et al. Developmental delay in Rett syndrome: data from the natural history study. J Neurodev Disord. 2014;6(1):20. doi: 10.1186/1866-1955-6-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1866-1955-6-20</ArticleId><ArticleId IdType="pmc">PMC4112822</ArticleId><ArticleId IdType="pubmed">25071871</ArticleId></ArticleIdList></Reference><Reference><Citation>Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci USA. 2004;101(16):6033&#x2013;6038. doi: 10.1073/pnas.0401626101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401626101</ArticleId><ArticleId IdType="pmc">PMC395918</ArticleId><ArticleId IdType="pubmed">15069197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen DR, Matarazzo V, Palmer AM, Tu Y, Jeon O-H, Pevsner J, et al. Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis. Mol Cell Neurosci. 2003;22(4):417&#x2013;429. doi: 10.1016/s1044-7431(03)00026-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1044-7431(03)00026-5</ArticleId><ArticleId IdType="pubmed">12727440</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 2003;302(5646):885&#x2013;889. doi: 10.1126/science.1086446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086446</ArticleId><ArticleId IdType="pubmed">14593183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci Lett. 2008;440(1):19&#x2013;22. doi: 10.1016/j.neulet.2008.05.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.05.055</ArticleId><ArticleId IdType="pubmed">18547721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysona BA, Zhao J, Smith S, Bollinger KE. Relationship between Sigma-1 receptor and BDNF in the visual system. Exp Eye Res. 2018;167:25&#x2013;30. doi: 10.1016/j.exer.2017.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2017.10.012</ArticleId><ArticleId IdType="pmc">PMC5757370</ArticleId><ArticleId IdType="pubmed">29031856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15&#x2013;29. doi: 10.1016/j.pneurobio.2012.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2012.09.001</ArticleId><ArticleId IdType="pubmed">23044468</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano M, Osada K, Misonoo A, Fujiwara K, Takahashi M, Ogawa Y, et al. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells. Life Sci. 2010;86(9&#x2013;10):309&#x2013;314. doi: 10.1016/j.lfs.2009.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2009.11.017</ArticleId><ArticleId IdType="pubmed">19995565</ArticleId></ArticleIdList></Reference><Reference><Citation>Christ MG, Clement AM, Behl C. The sigma-1 receptor at the crossroad of proteostasis, neurodegeneration, and autophagy. Trends Neurosci. 2020;43(2):79&#x2013;81. doi: 10.1016/j.tins.2019.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2019.12.002</ArticleId><ArticleId IdType="pubmed">31918966</ArticleId></ArticleIdList></Reference><Reference><Citation>Urano F. Wolfram syndrome: diagnosis, management, and treatment. Curr Diab Rep. 2016;16(1):6. doi: 10.1007/s11892-015-0702-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-015-0702-6</ArticleId><ArticleId IdType="pmc">PMC4705145</ArticleId><ArticleId IdType="pubmed">26742931</ArticleId></ArticleIdList></Reference><Reference><Citation>Abreu D, Urano F. Current landscape of treatments for Wolfram syndrome. Trends Pharmacol Sci. 2019;40(10):711&#x2013;714. doi: 10.1016/j.tips.2019.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.07.011</ArticleId><ArticleId IdType="pmc">PMC7547529</ArticleId><ArticleId IdType="pubmed">31420094</ArticleId></ArticleIdList></Reference><Reference><Citation>Delprat B, Maurice T, Delettre C. Wolfram syndrome: MAMs&#x2019; connection? Cell Death Dis. 2018;9(3):364. doi: 10.1038/s41419-018-0406-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0406-3</ArticleId><ArticleId IdType="pmc">PMC5840383</ArticleId><ArticleId IdType="pubmed">29511163</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori T, Hayashi T, Hayashi E, Su TP. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS ONE. 2013;8(10):e76941. doi: 10.1371/journal.pone.0076941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076941</ArticleId><ArticleId IdType="pmc">PMC3799859</ArticleId><ArticleId IdType="pubmed">24204710</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouzier L, Danese A, Yasui Y, Richard EM, Li&#xe9;vens J-C, Patergnani S, et al. Activation of the sigma-1 receptor chaperone alleviates symptoms of Wolfram syndrome in preclinical models. Sci Transl Med. 2022;14(631):eabh3763. doi: 10.1126/scitranslmed.abh3763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abh3763</ArticleId><ArticleId IdType="pmc">PMC9516885</ArticleId><ArticleId IdType="pubmed">35138910</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J, Bormann J, H&#xfc;bers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206(4):297&#x2013;300. doi: 10.1016/0922-4106(91)90113-v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0922-4106(91)90113-v</ArticleId><ArticleId IdType="pubmed">1717296</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005;25(13):3312&#x2013;3322. doi: 10.1523/jneurosci.4262-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.4262-04.2005</ArticleId><ArticleId IdType="pmc">PMC6724906</ArticleId><ArticleId IdType="pubmed">15800186</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E. Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci. 2004;19(8):2212&#x2013;2220. doi: 10.1111/j.0953-816X.2004.03297.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0953-816X.2004.03297.x</ArticleId><ArticleId IdType="pubmed">15090047</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas H. Expression of sigma receptors in human cancer cell lines and effects of novel sigma-2 ligands on their proliferation [Doctoral Thesis]. In. The University of Wolverhampton open repository. 2018. http://hdl.handle.net/2436/621768. Accessed 1 Dec 2022.</Citation></Reference><Reference><Citation>Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096&#x2013;1099. doi: 10.1212/WNL.0b013e31824e8f0d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31824e8f0d</ArticleId><ArticleId IdType="pubmed">22474298</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C, Ramphul K. Amantadine. In: Aboubakr S, Abu-Ghosh A, Acharya A, Adibi Sedeh P, Aeby T, Aeddula N, et al. Editors. StatPearls. Treasure Island (FL): StatPearls Publishing. 2023. https://www.ncbi.nlm.nih.gov/books/NBK499953/.</Citation></Reference><Reference><Citation>Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson&#x2019;s disease. JAMA. 1969;208(7):1168&#x2013;1170. doi: 10.1001/jama.1969.03160070046011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1969.03160070046011</ArticleId><ArticleId IdType="pubmed">5818715</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson&#x2019;s disease and other movement disorders. Lancet Neurol. 2021;20(12):1048&#x2013;1056. doi: 10.1016/S1474-4422(21)00249-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00249-0</ArticleId><ArticleId IdType="pubmed">34678171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the &#x3c3; binding site in post-mortem human frontal cortex. Neurosci Lett. 1993;163(2):129&#x2013;131. doi: 10.1016/0304-3940(93)90362-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(93)90362-O</ArticleId><ArticleId IdType="pubmed">8309617</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson&#x2019;s disease. Cochrane Database Syst Rev. 2003;2003(2):CD003467. doi: 10.1002/14651858.Cd003467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.Cd003467</ArticleId><ArticleId IdType="pmc">PMC8715285</ArticleId><ArticleId IdType="pubmed">12804468</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14(1):35&#x2013;51. doi: 10.2165/00003088-198814010-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-198814010-00003</ArticleId><ArticleId IdType="pubmed">3280212</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Salama ZT. Amantadine extended release capsules (GOCOVRI) in Parkinson&#x2019;s disease: a profile of its use in the USA. Drugs Ther Perspect. 2022;38(5):203&#x2013;214. doi: 10.1007/s40267-022-00912-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40267-022-00912-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser RA, Mehta SH, Kremens D, et al. Effects of Gocovri (amantadine) extended-release capsules on motor aspects of experiences of daily living in people with Parkinson&#x2019;s disease and dyskinesia. Neurol Ther. 2021;10(2):739&#x2013;751. doi: 10.1007/s40120-021-00256-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-021-00256-1</ArticleId><ArticleId IdType="pmc">PMC8571461</ArticleId><ArticleId IdType="pubmed">34024025</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmer LW, Juncos JL, Singer C, et al. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson&#x2019;s disease. CNS Drugs. 2018;32:387&#x2013;398. doi: 10.1007/s40263-018-0498-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-018-0498-4</ArticleId><ArticleId IdType="pmc">PMC5934466</ArticleId><ArticleId IdType="pubmed">29532440</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacson SH, Fahn S, Pahwa R, et al. Parkinson&#x2019;s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102. Mov Disord Clin Pract. 2018;5:183&#x2013;190. doi: 10.1002/mdc3.12595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.12595</ArticleId><ArticleId IdType="pmc">PMC5947645</ArticleId><ArticleId IdType="pubmed">29780852</ArticleId></ArticleIdList></Reference><Reference><Citation>Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson&#x2019;s disease (EASE LID 3) Mov Disord. 2017;32(12):1701&#x2013;1709. doi: 10.1002/mds.27131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27131</ArticleId><ArticleId IdType="pmc">PMC5763269</ArticleId><ArticleId IdType="pubmed">28833562</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941&#x2013;949. doi: 10.1001/jamaneurol.2017.0943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0943</ArticleId><ArticleId IdType="pmc">PMC5710325</ArticleId><ArticleId IdType="pubmed">28604926</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, et al. EASE LID 2: a 2-year open-label trial of gocovri (amantadine) extended release for dyskinesia in Parkinson&#x2019;s disease. J Parkinsons Dis. 2020;10(2):543&#x2013;558. doi: 10.3233/JPD-191841.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-191841</ArticleId><ArticleId IdType="pmc">PMC7242830</ArticleId><ArticleId IdType="pubmed">31929122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol. 1988;45(10):1104&#x2013;1106. doi: 10.1001/archneur.1988.00520340058012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1988.00520340058012</ArticleId><ArticleId IdType="pubmed">2972270</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res. 2012;34(9):854&#x2013;858. doi: 10.1179/1743132812Y.0000000081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1743132812Y.0000000081</ArticleId><ArticleId IdType="pubmed">22979982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis&#x2013;result of a pilot randomized, blind study. Clin Neurol Neurosurg. 2013;115:S86&#x2013;S89. doi: 10.1016/j.clineuro.2013.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2013.09.029</ArticleId><ArticleId IdType="pubmed">24321164</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazaei M, Karevan A, Taheri M, Ghafouri-Fard S. Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis. Clin Transl Med. 2019;8(1):20. doi: 10.1186/s40169-019-0239-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-019-0239-4</ArticleId><ArticleId IdType="pmc">PMC6603072</ArticleId><ArticleId IdType="pubmed">31263986</ArticleId></ArticleIdList></Reference><Reference><Citation>Puca F, Bricolo A, Turella G. Effect of L-dopa or amantadine therapy on sleep spindles in Parkinsonism. Electroencephalogr Clin Neurophysiol. 1973;35(3):327&#x2013;330. doi: 10.1016/0013-4694(73)90245-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0013-4694(73)90245-9</ArticleId><ArticleId IdType="pubmed">4126184</ArticleId></ArticleIdList></Reference><Reference><Citation>Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021;20(1):38&#x2013;48. doi: 10.1016/s1474-4422(20)30354-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(20)30354-9</ArticleId><ArticleId IdType="pmc">PMC7772747</ArticleId><ArticleId IdType="pubmed">33242419</ArticleId></ArticleIdList></Reference><Reference><Citation>Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (&#x3c3;1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011;25(8):1101&#x2013;1117. doi: 10.1177/0269881110379286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881110379286</ArticleId><ArticleId IdType="pubmed">20829307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahmy V, Meunier J, Malmstr&#xf6;m S, Naert G, Givalois L, Kim SH, et al. Blockade of Tau hyperphosphorylation and A&#x3b2; 1&#x2013;42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and &#x3c3; 1 receptor agonist, in a nontransgenic mouse model of Alzheimer&#x2019;s disease. Neuropsychopharmacology. 2013;38(9):1706. doi: 10.1038/npp.2013.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2013.70</ArticleId><ArticleId IdType="pmc">PMC3717544</ArticleId><ArticleId IdType="pubmed">23493042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahmy V, Long R, Morin D, Villard V, Maurice T. Mitochondrial protection by the mixed muscarinic/&#x3c3;1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A&#x3b2;25&#x2013;35 peptide-injected mice, a nontransgenic Alzheimer&#x2019;s disease model. Front Cell Neurosci. 2015;8:463. doi: 10.3389/fncel.2014.00463.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00463</ArticleId><ArticleId IdType="pmc">PMC4299448</ArticleId><ArticleId IdType="pubmed">25653589</ArticleId></ArticleIdList></Reference><Reference><Citation>Voges O, Weigmann I, Bitterlich N, Missling C, Schindler C. A Phase I dose escalation study to investigate safety, tolerability, and pharmacokinetics of ANAVEX 2&#x2010;73 in Healthy Male Subjects. Innov Clin Neurosci. 2014;12(Suppl B), 1-20; CNS Summit 2014, Boca Raton, Florida.</Citation></Reference><Reference><Citation>Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimers Dement. 2020;6(1):e12013. doi: 10.1002/trc2.12013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12013</ArticleId><ArticleId IdType="pmc">PMC7167374</ArticleId><ArticleId IdType="pubmed">32318621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisak RP, Nedelkoska L, Benjamins JA. Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis. J Neuroimmunol. 2020;342:577188. doi: 10.1016/j.jneuroim.2020.577188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2020.577188</ArticleId><ArticleId IdType="pubmed">32179326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann WE, Sprouse J, Rebowe N, Hanania T, Klamer D, Missling CU. ANAVEX 2&#x2013;73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome. Pharmacol Biochem Behav. 2019;187:172796. doi: 10.1016/j.pbb.2019.172796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2019.172796</ArticleId><ArticleId IdType="pubmed">31704481</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes ST, Deacon RM, Guo SG, Altimiras FJ, Castillo JB, van der Wildt B, et al. Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy. Sci Rep. 2021;11(1):17150. doi: 10.1038/s41598-021-94079-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94079-7</ArticleId><ArticleId IdType="pmc">PMC8387417</ArticleId><ArticleId IdType="pubmed">34433831</ArticleId></ArticleIdList></Reference><Reference><Citation>Anavex-Life-Sciences-Corp. ANAVEX2-73 (Blarcamesine) AVATAR phase 3 trial met primary and secondary efficacy endpoints. In: Anavex press release. 2022. https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints. Accessed 1 Nov 2022.</Citation></Reference><Reference><Citation>Hall H, Iulita MF, Gubert P, Flores Aguilar L, Ducatenzeiler A, Fisher A, et al. AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(6):811&#x2013;823. doi: 10.1016/j.jalz.2017.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.11.009</ArticleId><ArticleId IdType="pubmed">29291374</ArticleId></ArticleIdList></Reference><Reference><Citation>Anavex-life-Sciences-Corp. Anavex Life Sciences reports positive results from phase 1 clinical trial of ANAVEX3-71. In: Anavex press release. 2022. https://www.anavex.com/post/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71. Accessed 1 Nov 2022.</Citation></Reference><Reference><Citation>Rishton GM, Look GC, Ni ZJ, Zhang J, Wang Y, Huang Y, et al. Discovery of investigational drug CT1812, an antagonist of the Sigma-2 receptor complex for Alzheimer&#x2019;s disease. ACS Med Chem Lett. 2021;12(9):1389&#x2013;1395. doi: 10.1021/acsmedchemlett.1c00048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.1c00048</ArticleId><ArticleId IdType="pmc">PMC8436239</ArticleId><ArticleId IdType="pubmed">34531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, et al. Alzheimer's therapeutics targeting amyloid beta 1&#x2013;42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS ONE. 2014;9(11):e111899. doi: 10.1371/journal.pone.0111899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111899</ArticleId><ArticleId IdType="pmc">PMC4229119</ArticleId><ArticleId IdType="pubmed">25390692</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, et al. Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer's disease modification. Alzheimers Dement. 2021;17(8):1365&#x2013;1382. doi: 10.1371/journal.pone.0111899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111899</ArticleId><ArticleId IdType="pmc">PMC8349378</ArticleId><ArticleId IdType="pubmed">33559354</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper AR, Nayee S, Topol EJ. Protective alleles and modifier variants in human health and disease. Nat Rev Genet. 2015;16(12):689&#x2013;701. doi: 10.1038/nrg4017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg4017</ArticleId><ArticleId IdType="pubmed">26503796</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, et al. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer&#x2019;s disease. Alzheimers Dement. 2019;5:20&#x2013;26. doi: 10.1016/j.trci.2018.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6352291</ArticleId><ArticleId IdType="pubmed">30723776</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalano S, Grundman M, Schneider LS, DeKosky S, Morgan R, Guttendorf R, et al. [P4&#x2013;567]: a phase 1 safety trial of the A&#x3b2; oligomer receptor antagonist CT1812. Alzheimers Dement. 2017;13(7S):P1523&#x2013;P1580. doi: 10.1016/j.jalz.2017.07.730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.07.730</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz AR, Pizon AF, Brooks DE. Dextromethorphan-induced serotonin syndrome. Clin Toxicol. 2008;46(8):771&#x2013;773. doi: 10.1080/15563650701668625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15563650701668625</ArticleId><ArticleId IdType="pubmed">19238739</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin EJ, Nah SY, Chae JS, Bing G, Shin SW, Yen TP, et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats. Neurochem Int. 2007;50(6):791&#x2013;799. doi: 10.1016/j.neuint.2007.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2007.01.008</ArticleId><ArticleId IdType="pubmed">17386960</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1&#x2013;22. doi: 10.1016/j.pharmthera.2016.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2016.01.016</ArticleId><ArticleId IdType="pubmed">26826604</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauv&#xe9; WM. Recognizing and treating pseudobulbar affect. CNS Spectr. 2016;21(S1):34&#x2013;44. doi: 10.1017/S1092852916000791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1092852916000791</ArticleId><ArticleId IdType="pubmed">28044945</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnock-Jones KP. Dextromethorphan/quinidine. CNS Drugs. 2011;25(5):435&#x2013;445. doi: 10.2165/11207260-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11207260-000000000-00000</ArticleId><ArticleId IdType="pubmed">21476614</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242&#x2013;1254. doi: 10.1001/jama.2015.10214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.10214</ArticleId><ArticleId IdType="pubmed">26393847</ArticleId></ArticleIdList></Reference><Reference><Citation>Senanarong V, Cummings J, Fairbanks L, Mega M, Masterman D, O&#x2019;connor S, et al. Agitation in Alzheimer&#x2019;s disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord. 2004;17(1&#x2013;2):14&#x2013;20. doi: 10.1159/000074080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000074080</ArticleId><ArticleId IdType="pubmed">14560060</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Gorman C, Jones A, Cummings JL, et al. Efficacy and safety of AXS&#x2010;05, a novel, oral, NMDA&#x2010;receptor antagonist with multimodal activity, in agitation associated with Alzheimer&#x2019;s disease: results from ADVANCE&#x2010;1, a phase 2/3, double&#x2010;blind, active and placebo&#x2010;controlled trial: developments in clinical trials and cognitive assessment. Alzheimer Dement. 2020;16:e047684. doi: 10.1002/alz.047684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.047684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou Y-C, Liao J-F, Chang W-Y, Lin M-F, Chen C-F. Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999;821(2):516&#x2013;519. doi: 10.1016/s0006-8993(99)01125-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0006-8993(99)01125-7</ArticleId><ArticleId IdType="pubmed">10064839</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhagen Metman L, Del Dotto P, Natt&#xe9; R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson&#x2019;s disease. Neurology. 1998;51(1):203&#x2013;206. doi: 10.1212/wnl.51.1.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.51.1.203</ArticleId><ArticleId IdType="pubmed">9674803</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr MS, Starr BS, Kaur S. Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson&#x2019;s disease. Neurosci Biobehav Rev. 1997;21(4):437&#x2013;446. doi: 10.1016/s0149-7634(96)00039-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0149-7634(96)00039-5</ArticleId><ArticleId IdType="pubmed">9195601</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquette MA, Brudney EG, Putterman DB, Meshul CK, Johnson SW, Berger SP. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. NeuroReport. 2008;19(1):111&#x2013;115. doi: 10.1097/WNR.0b013e3282f3b0d1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0b013e3282f3b0d1</ArticleId><ArticleId IdType="pmc">PMC2845294</ArticleId><ArticleId IdType="pubmed">18281903</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-T, Kao L-T, Shih J-H, Chien W-C, Chiu C-H, Ma K-H, et al. The effect of dextromethorphan use in Parkinson&#x2019;s disease: a 6-hydroxydopamine rat model and population-based study. Eur J Pharmacol. 2019;862:172639. doi: 10.1016/j.ejphar.2019.172639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2019.172639</ArticleId><ArticleId IdType="pubmed">31491406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, et al. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson&#x2019;s disease. Mov Disord. 2017;32(6):893&#x2013;903. doi: 10.1002/mds.26976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26976</ArticleId><ArticleId IdType="pubmed">28370447</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natt&#xe9; R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord. 1998;13(3):414&#x2013;417. doi: 10.1002/mds.870130307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.870130307</ArticleId><ArticleId IdType="pubmed">9613730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm R, Ahl B, Anghelescu I-G. Dextrometorphan-paroxetine, but not dronabinol, effective for treatment-resistant aggression and agitation in an elderly patient with Lewy body dementia. J Clin Psychopharmacol. 2017;37(6):745&#x2013;747. doi: 10.1097/jcp.0000000000000805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/jcp.0000000000000805</ArticleId><ArticleId IdType="pubmed">29035934</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan BK, Yeakel JK, Goldfogel G, Frost MP, Sandstrom G, Wickham DJ. Dextromethorphan abuse leading to assault, suicide, or homicide. J Forensic Sci. 2012;57(5):1388&#x2013;1394. doi: 10.1111/j.1556-4029.2012.02133.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1556-4029.2012.02133.x</ArticleId><ArticleId IdType="pubmed">22537430</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial. Neurotherapeutics. 2017;14(3):762&#x2013;772. doi: 10.1007/s13311-016-0508-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JR, Allison KM, Cordella C, Richburg BD, Pattee GL, Berry JD, et al. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: a quantitative speech analysis. Br J Clin Pharmacol. 2018;84(12):2849&#x2013;2856. doi: 10.1111/bcp.13745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13745</ArticleId><ArticleId IdType="pmc">PMC6256051</ArticleId><ArticleId IdType="pubmed">30152872</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancho J, Ferrer S, Bur&#xe9;s E, D&#xed;az JL, Torrecilla T, Signes-Costa J, et al. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis. Respir Med. 2021;186:106536. doi: 10.1016/j.rmed.2021.106536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2021.106536</ArticleId><ArticleId IdType="pubmed">34260979</ArticleId></ArticleIdList></Reference><Reference><Citation>Chechneva OV, Mayrhofer F, Daugherty DJ, Pleasure DE, Hong J-S, Deng W. Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. Neurobiol Dis. 2011;44(1):63&#x2013;72. doi: 10.1016/j.nbd.2011.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.06.004</ArticleId><ArticleId IdType="pmc">PMC3153572</ArticleId><ArticleId IdType="pubmed">21704706</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisak RP, Nedelkoska L, Benjamins JA. Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules. Glia. 2014;62(5):751&#x2013;762. doi: 10.1002/glia.22639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22639</ArticleId><ArticleId IdType="pubmed">24526455</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693&#x2013;702. doi: 10.1002/ana.22093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22093</ArticleId><ArticleId IdType="pubmed">20839238</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrane I, VandenBerg A, Munjal R. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis. Ann Pharmacother. 2017;51(11):1035&#x2013;1036. doi: 10.1177/1060028017720746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1060028017720746</ArticleId><ArticleId IdType="pubmed">28691510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehde DM, Osborne TL, Jensen MP. Chronic pain in persons with multiple sclerosis. Phys Med Rehabil Clin N Am. 2005;16(2):503&#x2013;512. doi: 10.1016/j.pmr.2005.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmr.2005.01.001</ArticleId><ArticleId IdType="pubmed">15893684</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlos M, Romero L, Zamanillo D, Plata-Salam&#xe1;n C, Vela JM. Sigma-1 receptor and pain. Handb Exp Pharmacol. 2017;244:131&#x2013;161. doi: 10.1007/164_2017_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/164_2017_9</ArticleId><ArticleId IdType="pubmed">28275913</ArticleId></ArticleIdList></Reference><Reference><Citation>Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780&#x2013;787. doi: 10.1002/ana.20828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20828</ArticleId><ArticleId IdType="pubmed">16634036</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48(5):1212&#x2013;1218. doi: 10.1212/wnl.48.5.1212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.48.5.1212</ArticleId><ArticleId IdType="pubmed">9153445</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham RB, Marouani N, Kollender Y, Meller I, Weinbroum AA. Dextromethorphan for phantom pain attenuation in cancer amputees: a double-blind crossover trial involving three patients. Clin J Pain. 2002;18(5):282&#x2013;285. doi: 10.1097/00002508-200209000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002508-200209000-00002</ArticleId><ArticleId IdType="pubmed">12218498</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson K, Hoem N, Moberg E, Mathisen L. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand. 2004;48(3):328&#x2013;336. doi: 10.1111/j.0001-5172.2004.0325.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0001-5172.2004.0325.x</ArticleId><ArticleId IdType="pubmed">14982566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilron I, Booher S, Rowan J, Smoller B, Max M. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology. 2000;55(7):964&#x2013;971. doi: 10.1212/wnl.55.7.964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.55.7.964</ArticleId><ArticleId IdType="pubmed">11061252</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuay HJ, Carroll D, Jadad AR, Glynn CJ, Jack T, Moore RA, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain. 1994;59(1):127&#x2013;133. doi: 10.1016/0304-3959(94)90056-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3959(94)90056-6</ArticleId><ArticleId IdType="pubmed">7854793</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Hicks CL, Gupta S, Ewen JB, Hong M, Kratz L, Kelley R, Tierney E, Vaurio R, Bibat G, Sanyal A, Yenokyan G, Brereton N, Johnston MV, Naidu S. Randomized open-label trial of dextromethorphan in Rett syndrome. Neurology. 2017;89(16):1684&#x2013;1690. doi: 10.1212/WNL.0000000000004515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004515</ArticleId><ArticleId IdType="pmc">PMC5644464</ArticleId><ArticleId IdType="pubmed">28931647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumagai K, Shono K, Nakayama H, Ohno Y, Sajai I. (2R-trans)-2-butyl-5-heptylpyrrolidine as a potent sigma receptor ligand produced by Streptomyces longispororuber. Journal Antibiot. 2000;53(5):467&#x2013;473. doi: 10.7164/antibiotics.53.467.</Citation><ArticleIdList><ArticleId IdType="doi">10.7164/antibiotics.53.467</ArticleId><ArticleId IdType="pubmed">10908109</ArticleId></ArticleIdList></Reference><Reference><Citation>Moebius FF, Reiter RJ, Hanner M, Glossmann H. High affinity of sigma1-binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8&#x2013;C7 isomerase. Br J Pharmacol. 1997;121(1):1&#x2013;6. doi: 10.1038/sj.bjp.0701079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0701079</ArticleId><ArticleId IdType="pmc">PMC1564641</ArticleId><ArticleId IdType="pubmed">9146879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran S, Chu UB, Mavlyutov TA, Pal A, Pyne S, Ruoho AE. The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur J Pharmacol. 2009;609(1&#x2013;3):19&#x2013;26. doi: 10.1016/j.ejphar.2009.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2009.03.003</ArticleId><ArticleId IdType="pmc">PMC3194046</ArticleId><ArticleId IdType="pubmed">19285059</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Satyshur K, Guo LW, Ruoho AE. Sphingoid bases regulate the Sigma-1 receptor&#x2014;sphingosine and N,N&#x2019;-dimethylsphingosine are endogenous agonists. Int J Mol Sci. 24(4):3103; Doi: 10.3390/ijms24043103</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9962145</ArticleId><ArticleId IdType="pubmed">36834510</ArticleId></ArticleIdList></Reference><Reference><Citation>National-Institute-for-Health-and-Care-Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#x2019;s disease. In: National Institute for Heath Care Excelence. 2011;TA217:1-77; https://www.nice.org.uk/guidance/ta217. Accessed 1 Nov 2022.</Citation></Reference><Reference><Citation>Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett. 1999;260(1):5&#x2013;8. doi: 10.1016/S0304-3940(98)00943-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(98)00943-4</ArticleId><ArticleId IdType="pubmed">10027686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan NK, Visser AK, Schepers M, Luurtsema G, Nyakas CJ, Elsinga PH, et al. Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with 11 C-SA4503 and microPET. Psychopharmacology. 2014;231(20):3997&#x2013;4006. doi: 10.1007/s00213-014-3533-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-014-3533-2</ArticleId><ArticleId IdType="pubmed">24639047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J, et al. The effect of donepezil treatment on cardiovascular mortality. Clin Pharmacol Ther. 2010;88(3):335&#x2013;338. doi: 10.1038/clpt.2010.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2010.98</ArticleId><ArticleId IdType="pmc">PMC3120840</ArticleId><ArticleId IdType="pubmed">20664535</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer&#x2019;s disease. Eur Heart J. 2013;34(33):2585&#x2013;2591. doi: 10.1093/eurheartj/eht182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht182</ArticleId><ArticleId IdType="pubmed">23735859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhuiyan MS, Fukunaga K. Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection. Expert Opin Ther Targets. 2011;15(2):145&#x2013;155. doi: 10.1517/14728222.2011.546350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2011.546350</ArticleId><ArticleId IdType="pubmed">21204730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1656&#x2013;1659. doi: 10.1016/j.pnpbp.2008.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2008.06.011</ArticleId><ArticleId IdType="pubmed">18647636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Lian S, Zhang Y, Zhao Q. Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2022;213:107134. doi: 10.1016/j.clineuro.2022.107134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2022.107134</ArticleId><ArticleId IdType="pubmed">35078087</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer&#x2019;s disease. Cochrane Database Syst Rev. 2018;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001190.pub3</ArticleId><ArticleId IdType="pubmed">12917900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Zong Y, Han Y, Zhao J, Liu H, Liu Y. Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21(3):407&#x2013;415. doi: 10.1080/14740338.2022.2027905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2022.2027905</ArticleId><ArticleId IdType="pubmed">35099343</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer&#x2019;s disease. N Engl J Med. 2012;366(10):893&#x2013;903. doi: 10.1056/NEJMoa1106668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1106668</ArticleId><ArticleId IdType="pubmed">22397651</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer&#x2019;s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590&#x2013;1599. doi: 10.1111/j.1532-5415.2001.49266.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2001.49266.x</ArticleId><ArticleId IdType="pubmed">11843990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye CY, Lei Y, Tang XC, Zhang HY. Donepezil attenuates A&#x3b2;-associated mitochondrial dysfunction and reduces mitochondrial A&#x3b2; accumulation in vivo and in vitro. Neuropharmacology. 2015;95:29&#x2013;36. doi: 10.1016/j.neuropharm.2015.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.02.020</ArticleId><ArticleId IdType="pubmed">25744714</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Yuede CM, Coughlan CA, Murphy KM, Csernansky JG. Effects of donepezil on amyloid-&#x3b2; and synapse density in the Tg2576 mouse model of Alzheimer&#x2019;s disease. Brain Res. 2009;1303:169&#x2013;178. doi: 10.1016/j.brainres.2009.09.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.09.097</ArticleId><ArticleId IdType="pmc">PMC2789417</ArticleId><ArticleId IdType="pubmed">19799879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi K, Miura Y, Wagatsuma K, Ishiwata K, Ishii K. Changes in brain amyloid-&#x3b2; accumulation after donepezil administration. J Clin Neurosci. 2017;45:328&#x2013;329. doi: 10.1016/j.jocn.2017.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2017.08.025</ArticleId><ArticleId IdType="pubmed">28864409</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer&#x2019;s disease. N Engl J Med. 2007;357(14):1382&#x2013;1392. doi: 10.1056/NEJMoa066583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa066583</ArticleId><ArticleId IdType="pubmed">17914039</ArticleId></ArticleIdList></Reference><Reference><Citation>De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. 1999;22(12):535&#x2013;540. doi: 10.1016/s0166-2236(99)01463-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0166-2236(99)01463-0</ArticleId><ArticleId IdType="pubmed">10542428</ArticleId></ArticleIdList></Reference><Reference><Citation>Modell S, Naber D, Holzbach R. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Pharmacopsychiatry. 1996;29(02):63&#x2013;66. doi: 10.1055/s-2007-979546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-979546</ArticleId><ArticleId IdType="pubmed">8741023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K, London ED. Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of &#x3c3; receptors. Eur J Pharmacol. 1995;273(3):307&#x2013;310. doi: 10.1016/0014-2999(94)00763-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(94)00763-w</ArticleId><ArticleId IdType="pubmed">7737340</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks S, Kaur S, Starr BS, Starr MS. Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson&#x2019;s disease? J Neural Transm (Vienna) 1996;103(6):737&#x2013;748. doi: 10.1007/bf01271233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf01271233</ArticleId><ArticleId IdType="pubmed">8836935</ArticleId></ArticleIdList></Reference><Reference><Citation>Demerens C, Stankoff B, Zalc B, Lubetzki C. Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis? Neurology. 1999;52(2):346. doi: 10.1212/wnl.52.2.346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.52.2.346</ArticleId><ArticleId IdType="pubmed">9932955</ArticleId></ArticleIdList></Reference><Reference><Citation>Silkina I, Gan'shina T, Seredin S, Mirzoian R. Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon. E Eksp Klin Farmakol. 2005;68(1):20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">15786959</ArticleId></ArticleIdList></Reference><Reference><Citation>Antipova T, Sapozhnikova D, Liu B, Seredenin S. Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons. Eksp Klin Farmakol. 2009;72(1):12&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19334503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuevas J, Rodriguez A, Behensky A, Katnik C. Afobazole modulates microglial function via activation of both &#x3c3;-1 and &#x3c3;-2 receptors. J Pharmacol Exp Ther. 2011;339(1):161&#x2013;172. doi: 10.1124/jpet.111.182816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.111.182816</ArticleId><ArticleId IdType="pubmed">21715561</ArticleId></ArticleIdList></Reference><Reference><Citation>Behensky AA, Yasny IE, Shuster AM, Seredenin SB, Petrov AV, Cuevas J. Stimulation of sigma receptors with afobazole blocks activation of microglia and reduces toxicity caused by amyloid-&#x3b2;25&#x2013;35. J Pharmacol Exp Ther. 2013;347(2):458&#x2013;467. doi: 10.1124/jpet.113.208348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.113.208348</ArticleId><ArticleId IdType="pubmed">24006337</ArticleId></ArticleIdList></Reference><Reference><Citation>Behensky AA, Yasny IE, Shuster AM, Seredenin SB, Petrov AV, Cuevas J. Afobazole activation of &#x3c3;-1 receptors modulates neuronal responses to amyloid-&#x3b2;25&#x2013;35. J Pharmacol Exp Ther. 2013;347(2):468&#x2013;477. doi: 10.1124/jpet.113.208330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.113.208330</ArticleId><ArticleId IdType="pubmed">24006338</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin P, de-Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020;105:106989. 10.1016/j.yebeh.2020.106989.</Citation><ArticleIdList><ArticleId IdType="pubmed">32169824</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2021;16(4):373&#x2013;389. doi: 10.1080/17460441.2021.1838483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2021.1838483</ArticleId><ArticleId IdType="pubmed">33070647</ArticleId></ArticleIdList></Reference><Reference><Citation>Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554&#x2013;564. doi: 10.1001/jamaneurol.2022.0829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.0829</ArticleId><ArticleId IdType="pmc">PMC9062770</ArticleId><ArticleId IdType="pubmed">35499850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243&#x2013;2254. doi: 10.1016/S0140-6736(19)32500-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32500-0</ArticleId><ArticleId IdType="pubmed">31862249</ArticleId></ArticleIdList></Reference><Reference><Citation>Specchio N, Pietrafusa N, Doccini V, Trivisano M, Darra F, Ragona F, et al. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study. Epilepsia. 2020;61(11):2405&#x2013;2414. doi: 10.1111/epi.16690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.16690</ArticleId><ArticleId IdType="pubmed">32945537</ArticleId></ArticleIdList></Reference><Reference><Citation>Chomchoei C, Brimson J, Brimson S. Repurposing fluoxetine to treat lymphocytic leukaemia: apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction. Expert Opin Ther Targets. 2023 doi: 10.1080/14728222.2022.2166829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2022.2166829</ArticleId><ArticleId IdType="pubmed">36620917</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe9;meth ZK, Sz&#xfb;cs A, Vitrai J, Juh&#xe1;sz D, N&#xe9;meth JP, Holl&#xf3; A. Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study. Ideggyogy Sz. 2021;74(11&#x2013;12):389&#x2013;396. doi: 10.18071/isz.74.0389.</Citation><ArticleIdList><ArticleId IdType="doi">10.18071/isz.74.0389</ArticleId><ArticleId IdType="pubmed">34856085</ArticleId></ArticleIdList></Reference><Reference><Citation>Emilia M, Rosso D, Laura M, Mar&#xed;a A. Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug ? Pharmacol Res. 2016;109:101&#x2013;107. doi: 10.1016/j.phrs.2015.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2015.11.021</ArticleId><ArticleId IdType="pubmed">26644208</ArticleId></ArticleIdList></Reference><Reference><Citation>Safrany ST, Brimson JM. Are fluoxetine&#x2019;s effects due to sigma-1 receptor agonism? Pharmacol Res. 2016;113:707&#x2013;708. doi: 10.1016/j.phrs.2016.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.05.031</ArticleId><ArticleId IdType="pubmed">27262678</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, Van Buchem MA, et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry. 2008;79(9):1027&#x2013;1031. doi: 10.1136/jnnp.2007.139345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2007.139345</ArticleId><ArticleId IdType="pubmed">18450787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Kang SR, Yune TY. Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. J Neurotrauma. 2015;32(9):633&#x2013;644. doi: 10.1089/neu.2014.3527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2014.3527</ArticleId><ArticleId IdType="pmc">PMC4410451</ArticleId><ArticleId IdType="pubmed">25366938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sijens PE, Mostert JP, Irwan R, Potze JH, Oudkerk M, De Keyser J. Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res. 2008;164(3):274&#x2013;282. doi: 10.1016/j.pscychresns.2007.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2007.12.014</ArticleId><ArticleId IdType="pubmed">19017554</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambron M, Mostert J, D&#x2019;Hooghe M, Nagels G, Willekens B, Debruyne J, et al. Fluoxetine in progressive multiple sclerosis: the FLUOX-PMS trial. Mult Scler J. 2019;25(13):1728&#x2013;1735. doi: 10.1177/1352458519843051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458519843051</ArticleId><ArticleId IdType="pubmed">31218911</ArticleId></ArticleIdList></Reference><Reference><Citation>Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, et al. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open. 2018;8(8):e021944. 10.1136/bmjopen-2018-021944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119433</ArticleId><ArticleId IdType="pubmed">30166303</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, et al. Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy Mech Eval. 2020;7(3):1&#x2013;72. doi: 10.3310/eme07030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/eme07030</ArticleId><ArticleId IdType="pubmed">32453521</ArticleId></ArticleIdList></Reference><Reference><Citation>Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, et al. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurol. 2020;19(3):214&#x2013;225. doi: 10.1016/S1474-4422(19)30485-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30485-5</ArticleId><ArticleId IdType="pmc">PMC7029307</ArticleId><ArticleId IdType="pubmed">31981516</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, Tencomnao T. Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the Sigma-1 receptor and autophagy. Expert Opin Ther Targets. 2021;25(6):35&#x2013;449. doi: 10.1080/14728222.2021.1952987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2021.1952987</ArticleId><ArticleId IdType="pmc">PMC8290373</ArticleId><ArticleId IdType="pubmed">34236922</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. 2008;3(7):e2558. doi: 10.1371/journal.pone.0002558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002558</ArticleId><ArticleId IdType="pmc">PMC2435603</ArticleId><ArticleId IdType="pubmed">18596927</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti F, Campori E, Colombo C, Smeraldi E. Fluvoxamine treatment of major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2004;16(3):364&#x2013;366. doi: 10.1176/jnp.16.3.364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/jnp.16.3.364</ArticleId><ArticleId IdType="pubmed">15377746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, et al. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci Rep. 2017;7(1):4923. doi: 10.1038/s41598-017-04968-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04968-z</ArticleId><ArticleId IdType="pmc">PMC5501834</ArticleId><ArticleId IdType="pubmed">28687730</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR. Evaluation of sigma (&#x3c3;) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol. 2012;22(4):308&#x2013;317. doi: 10.1016/j.euroneuro.2011.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2011.08.002</ArticleId><ArticleId IdType="pubmed">21911285</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikiforuk A, Popik P. Ketamine prevents stress-induced cognitive inflexibility in rats. Psychoneuroendocrinology. 2014;40:119&#x2013;122. doi: 10.1016/j.psyneuen.2013.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2013.11.009</ArticleId><ArticleId IdType="pubmed">24485483</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibakawa YS, Sasaki Y, Goshima Y, Echigo N, Kamiya Y, Kurahashi K, et al. Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide. Br J Anaesth. 2005;95(6):803&#x2013;810. doi: 10.1093/bja/aei256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aei256</ArticleId><ArticleId IdType="pubmed">16227338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger A, R&#xfc;st CA, Riegger H, Gysi B, Tran F, Br&#xfc;gger J, et al. Ketamine vs haloperidol for prevention of cognitive dysfunction and postoperative delirium: a phase IV multicentre randomised placebo-controlled double-blind clinical trial. J Clin Anesth. 2021;68:110099. doi: 10.1016/j.jclinane.2020.110099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2020.110099</ArticleId><ArticleId IdType="pubmed">33120302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013;16(9):2111&#x2013;2117. doi: 10.1017/S1461145713000485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1461145713000485</ArticleId><ArticleId IdType="pubmed">23683309</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MW, Ho RC. Controversies of the effect of ketamine on cognition. Front Psychiatry. 2016;7:47. doi: 10.3389/fpsyt.2016.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2016.00047</ArticleId><ArticleId IdType="pmc">PMC4809869</ArticleId><ArticleId IdType="pubmed">27065891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530&#x2013;538. doi: 10.1001/archpsyc.63.5.530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.5.530</ArticleId><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72(7):537&#x2013;47. 10.1016/j.biopsych.2012.05.003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438349</ArticleId><ArticleId IdType="pubmed">22705040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha FL, de Vasconcelos Cunha UG, Paschoalin RC, Hara C, Thomaz DP. Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer&#x2019;s disease. Int Clin Psychopharmacol. 2021;36(2):104&#x2013;105. doi: 10.1097/YIC.0000000000000334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YIC.0000000000000334</ArticleId><ArticleId IdType="pubmed">33230024</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Li H, Huang J, Huang S, Bai Y, Li Y, et al. Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: a systematic review and network meta-analysis. J Psychopharmacol. 2021;35(8):901&#x2013;909. doi: 10.1177/02698811211030181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02698811211030181</ArticleId><ArticleId IdType="pubmed">34238048</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung L, Wai MS, Fan M, Mak Y, Lam W, Li Z, et al. Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine. Toxicol Lett. 2010;193(2):189&#x2013;193. doi: 10.1016/j.toxlet.2010.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxlet.2010.01.008</ArticleId><ArticleId IdType="pubmed">20093173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro M, Angelucci M, Anselmo-Franci J, Canteras N, Da Cunha C. Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson&#x2019;s disease. Braz J Med Biol Res. 2007;40:89&#x2013;96. doi: 10.1590/s0100-879x2007000100012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0100-879x2007000100012</ArticleId><ArticleId IdType="pubmed">17225001</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchia DD, Kanazawa LKS, Wendler E, Hocayen PdAS, Vital MABF, Takahashi RN, et al. Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson&#x2019;s disease. Brain Res Bull. 2021;168:63&#x2013;73. 10.1016/j.brainresbull.2020.12.011.</Citation><ArticleIdList><ArticleId IdType="pubmed">33359641</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J-C, Song J-J, Wang Y, Chen Y, Hong D-X. Neuron-protective effect of subanesthestic-dosage ketamine on mice of Parkinson&#x2019;s disease. Asian Pac J Trop Med. 2017;10(10):1007&#x2013;1010. doi: 10.1016/j.apjtm.2017.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apjtm.2017.09.014</ArticleId><ArticleId IdType="pubmed">29111184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JJ, Goodnight PD, McEvoy MD. The utility of ketamine for the preoperative management of a patient with Parkinson&#x2019;s disease. Anesth Analg. 2009;108(3):980&#x2013;982. doi: 10.1213/ane.0b013e3181924025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0b013e3181924025</ArticleId><ArticleId IdType="pubmed">19224812</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar G, Motamed C. A remifentanil/ketamine sedation in surgical cancer patients having severe Parkinson&#x2019;s disease: two case reports. J Opioid Manag. 2012;8(2):133&#x2013;134. doi: 10.5055/jom.2012.0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.5055/jom.2012.0106</ArticleId><ArticleId IdType="pubmed">22616319</ArticleId></ArticleIdList></Reference><Reference><Citation>Barenboim I, Lafer B. Maintenance use of ketamine for treatment-resistant depression: an open-label pilot study. Braz J Psychiatry. 2018;40(1):110. doi: 10.1590/1516-4446-2017-2380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1516-4446-2017-2380</ArticleId><ArticleId IdType="pmc">PMC6899427</ArticleId><ArticleId IdType="pubmed">29590266</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketamine for treatment-resistant unipolar depression. CNS Drugs. 2012;26(3):189&#x2013;204. doi: 10.2165/11599770-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11599770-000000000-00000</ArticleId><ArticleId IdType="pmc">PMC3677048</ArticleId><ArticleId IdType="pubmed">22303887</ArticleId></ArticleIdList></Reference><Reference><Citation>Feifel D. Breaking sad: unleashing the breakthrough potential of k etamine&#x2019;s rapid antidepressant effects. Drug Dev Res. 2016;77(8):489&#x2013;494. doi: 10.1002/ddr.21347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21347</ArticleId><ArticleId IdType="pubmed">27888525</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2014;155:123&#x2013;129. doi: 10.1016/j.jad.2013.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2013.10.036</ArticleId><ArticleId IdType="pubmed">24268616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Chang L, Tan Y, Qu Y, Shan J, Hashimoto K. (R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice. Brain Res Bull. 2021;177:316&#x2013;323. doi: 10.1016/j.brainresbull.2021.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2021.10.013</ArticleId><ArticleId IdType="pubmed">34688833</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Chang L, Wan X, Tan Y, Qu Y, Shan J, et al. (R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: a role of gut&#x2013;microbiota&#x2013;brain axis. Neurobiol Dis. 2022;165:105635. doi: 10.1016/j.nbd.2022.105635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105635</ArticleId><ArticleId IdType="pubmed">35085752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai T, Tomiyasu S, Ono T, Yamada H, Sumikawa K. Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine. Clin J Pain. 2004;20(5):375&#x2013;376. doi: 10.1097/00002508-200409000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002508-200409000-00016</ArticleId><ArticleId IdType="pubmed">15322448</ArticleId></ArticleIdList></Reference><Reference><Citation>Messer MM, Haller IV. Ketamine therapy for treatment-resistant depression in a patient with multiple sclerosis: a case report. Innov Clin Neurosci. 2017;14(1&#x2013;2):56&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373796</ArticleId><ArticleId IdType="pubmed">28386522</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrizi A, Picard N, Simon AJ, Gunner G, Centofante E, Andrews NA, et al. Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype. Biol Psychiatry. 2016;79(9):755&#x2013;764. doi: 10.1016/j.biopsych.2015.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2015.08.018</ArticleId><ArticleId IdType="pmc">PMC7410367</ArticleId><ArticleId IdType="pubmed">26410354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kron M, Howell CJ, Adams IT, Ransbottom M, Christian D, Ogier M, et al. Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. J Neurosci. 2012;32(40):13860&#x2013;13872. doi: 10.1523/jneurosci.2159-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.2159-12.2012</ArticleId><ArticleId IdType="pmc">PMC3500840</ArticleId><ArticleId IdType="pubmed">23035095</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly T, McLean HS. Use of ketamine during procedural sedation: indications, controversies, and side effects. J Infus Nurs. 2012;35(6):377&#x2013;382. doi: 10.1097/NAN.0b013e31827068c1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NAN.0b013e31827068c1</ArticleId><ArticleId IdType="pubmed">23132086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mount C, Downton C. Alzheimer disease: progress or profit? Nat Med. 2006;12(7):780&#x2013;784. doi: 10.1038/nm0706-780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0706-780</ArticleId><ArticleId IdType="pubmed">16829947</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, donepezil, or combination therapy&#x2014;what is the best therapy for Alzheimer&#x2019;s disease? A network meta-analysis. Brain Behav. 2020;10(11):e01831. doi: 10.1002/brb3.1831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1831</ArticleId><ArticleId IdType="pmc">PMC7667299</ArticleId><ArticleId IdType="pubmed">32914577</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt HP. On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses. 2005;65(2):259&#x2013;265. doi: 10.1016/j.mehy.2005.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2005.03.011</ArticleId><ArticleId IdType="pubmed">15922097</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons C, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist&#x2014;a review of preclinical data. Neuropharmacol. 1999;38(6):735&#x2013;767. doi: 10.1016/s0028-3908(99)00019-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0028-3908(99)00019-2</ArticleId><ArticleId IdType="pubmed">10465680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer&#x2019;s disease. CNS Drug Rev. 2003;9(3):275&#x2013;308. doi: 10.1111/j.1527-3458.2003.tb00254.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1527-3458.2003.tb00254.x</ArticleId><ArticleId IdType="pmc">PMC6741669</ArticleId><ArticleId IdType="pubmed">14530799</ArticleId></ArticleIdList></Reference><Reference><Citation>Martina M, Turcotte MEB, Halman S, Bergeron R. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol. 2007;578(1):143&#x2013;157. doi: 10.1113/jphysiol.2006.116178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2006.116178</ArticleId><ArticleId IdType="pmc">PMC2075134</ArticleId><ArticleId IdType="pubmed">17068104</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaki S, Okuyama S, Ogawa S-i, Tomisawa K. Regulation of NMDA-induced [3H] dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochem Int. 1998;33(1):29&#x2013;34. 10.1113/jphysiol.2006.116178.</Citation><ArticleIdList><ArticleId IdType="pubmed">9694039</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha S, Qu WJ, Li L, Lu ZH, Chen L, Yu WF, et al. Sigma-1 receptor knockout impairs neurogenesis in dentate gyrus of adult hippocampus via down-regulation of NMDA receptors. CNS Neurosci Ther. 2013;19(9):705&#x2013;713. doi: 10.1111/cns.12129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12129</ArticleId><ArticleId IdType="pmc">PMC6493366</ArticleId><ArticleId IdType="pubmed">23745740</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabba M, Wong AY, Ahlskog N, Hristova E, Biscaro D, Nassrallah W, et al. NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. J Neurosci. 2014;34(34):11325&#x2013;11338. doi: 10.1523/JNEUROSCI.0458-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0458-14.2014</ArticleId><ArticleId IdType="pmc">PMC6615506</ArticleId><ArticleId IdType="pubmed">25143613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl SM. Mechanism of action of ketamine. CNS Spectr. 2013;18(4):171&#x2013;174. doi: 10.1017/S109285291300045X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S109285291300045X</ArticleId><ArticleId IdType="pubmed">23866089</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Jones RW, Wirth Y, St&#xf6;ffler A, M&#xf6;bius HJ. Memantine in moderate to severe Alzheimer&#x2019;s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20&#x2013;27. doi: 10.1159/000102568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000102568</ArticleId><ArticleId IdType="pubmed">17496417</ArticleId></ArticleIdList></Reference><Reference><Citation>Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer&#x2019;s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6. doi: 10.1186/alzrt160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt160</ArticleId><ArticleId IdType="pmc">PMC3580327</ArticleId><ArticleId IdType="pubmed">23336974</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt FA, van Dyck CH, Wichems CH, Olin JT, Group MM-M-S. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord. 2006;20(4):255&#x2013;62. 10.1097/01.wad.0000213860.35355.d4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132970</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600&#x2013;607. doi: 10.1136/jnnp.2008.158964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.158964</ArticleId><ArticleId IdType="pmc">PMC2823571</ArticleId><ArticleId IdType="pubmed">19204022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317&#x2013;324. doi: 10.1001/jama.291.3.317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.3.317</ArticleId><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrix S, Ellison N, Stanworth S, Otcheretko V, Tariot PN. Post Hoc Evidence for an additive effect of memantine and donepezil: consistent findings from DOMINO-AD Study and Memantine Clinical Trial Program. J Prev Alzheimers Dis. 2015;2(3):165&#x2013;171. doi: 10.14283/jpad.2015.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2015.66</ArticleId><ArticleId IdType="pubmed">29226942</ArticleId></ArticleIdList></Reference><Reference><Citation>Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer&#x2019;s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83&#x2013;89. doi: 10.2174/156720508783884576.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720508783884576</ArticleId><ArticleId IdType="pubmed">18288936</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson&#x2019;s disease. Mov Disord. 2009;24(8):1217&#x2013;1221. doi: 10.1002/mds.22495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22495</ArticleId><ArticleId IdType="pubmed">19370737</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M, Tsolaki M, Bonuccelli U, Dest&#xe9;e A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson&#x2019;s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969&#x2013;977. doi: 10.1016/S1474-4422(10)70194-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70194-0</ArticleId><ArticleId IdType="pubmed">20729148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ondo WG, Shinawi L, Davidson A, et al. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord. 2011;17(3):156&#x2013;159. doi: 10.1016/j.parkreldis.2010.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2010.12.003</ArticleId><ArticleId IdType="pubmed">21193343</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Delval A, Tiffreau V, et al. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry. 2013;84(5):552&#x2013;555. doi: 10.1136/jnnp-2012-303182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303182</ArticleId><ArticleId IdType="pmc">PMC3623038</ArticleId><ArticleId IdType="pubmed">23077087</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson&#x2019;s disease, Parkinson&#x2019;s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135&#x2013;143. doi: 10.1136/jnnp-2014-307659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307659</ArticleId><ArticleId IdType="pubmed">24828899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjay M, Amir G, John R, Scott O, Stephen D, et al. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008;30:9. doi: 10.1016/j.clinthera.2008.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2008.09.006</ArticleId><ArticleId IdType="pubmed">18840371</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Jr, et al. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008;28(2):235&#x2013;239. doi: 10.1097/JCP.0b013e31816774de.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCP.0b013e31816774de</ArticleId><ArticleId IdType="pubmed">18344738</ArticleId></ArticleIdList></Reference><Reference><Citation>PRX-00023 Therapy in localization-related epilepsy. In: NIH U.S. National Library of Medicine clinical trials web site; 2011. https://clinicaltrials.gov/ct2/show/NCT01281956. Accessed 1 Dec 2022.</Citation></Reference><Reference><Citation>Merritt HH, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. J Am Med Assoc. 1938;111(12):1068&#x2013;1073. doi: 10.1001/jama.1938.02790380010004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1938.02790380010004</ArticleId><ArticleId IdType="pubmed">6363736</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogawski MA, L&#xf6;scher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5(7):553&#x2013;564. doi: 10.1038/nrn1430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1430</ArticleId><ArticleId IdType="pubmed">15208697</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchedre KT, Huang RQ, Dibas A, Krishnamoorthy RR, Dillon GH, Yorio T. Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci. 2008;49(11):4993&#x2013;5002. doi: 10.1167/iovs.08-1867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.08-1867</ArticleId><ArticleId IdType="pubmed">18641291</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller BH, II, Park Y, Daudt DR, III, Ma H-Y, Akopova I, Stankowska DL, et al. Sigma-1 receptor stimulation attenuates calcium influx through activated L-type voltage gated calcium channels in purified retinal ganglion cells. Exp Eye Res. 2013;107:21&#x2013;31. doi: 10.1016/j.exer.2012.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2012.11.002</ArticleId><ArticleId IdType="pubmed">23183135</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Zhao Z, Lan L, Wei X, Wang L, Liu X, et al. Sigma-1 receptor plays a negative modulation on N-type calcium channel. Front Pharmacol. 2017;8:302. doi: 10.3389/fphar.2017.00302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00302</ArticleId><ArticleId IdType="pmc">PMC5445107</ArticleId><ArticleId IdType="pubmed">28603497</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Cuevas J. Sigma receptors inhibit high-voltage&#x2013;activated calcium channels in rat sympathetic and parasympathetic neurons. J Neurophysiol. 2002;87(6):2867&#x2013;2879. doi: 10.1152/jn.2002.87.6.2867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.2002.87.6.2867</ArticleId><ArticleId IdType="pubmed">12037190</ArticleId></ArticleIdList></Reference><Reference><Citation>DeHaven-Hudkins D, Ford-Rice F, Allen J, Hudkins R. Allosteric modulation of ligand binding to [3H](+) pentazocine-defined &#x3c3; recognition sites by phenytoin. Life Sci. 1993;53(1):41&#x2013;48. doi: 10.1016/0024-3205(93)90609-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0024-3205(93)90609-7</ArticleId><ArticleId IdType="pubmed">8515681</ArticleId></ArticleIdList></Reference><Reference><Citation>Braakman HM, Verhoeven JS, Erasmus CE, Haaxma CA, Willemsen MH, Schelhaas HJ. Phenytoin as a last-resort treatment in SCN 8A encephalopathy. Epilepsia Open. 2017;2(3):343&#x2013;344. doi: 10.1002/epi4.12059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/epi4.12059</ArticleId><ArticleId IdType="pmc">PMC5862112</ArticleId><ArticleId IdType="pubmed">29588963</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilena R, Striano P, Gennaro E, Bassi L, Olivotto S, Tadini L, et al. Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy. Brain Dev. 2017;39(4):345&#x2013;348. doi: 10.1016/j.braindev.2016.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.braindev.2016.10.015</ArticleId><ArticleId IdType="pubmed">27876397</ArticleId></ArticleIdList></Reference><Reference><Citation>Su TP, Wu XZ, Cone EJ, Shukla K, Gund TM, Dodge AL, et al. Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. J Pharmacol Exp Ther. 1991;259(2):543&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">1658302</ArticleId></ArticleIdList></Reference><Reference><Citation>Motawe ZY, Abdelmaboud SS, Cuevas J, Breslin JW. PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation. Int J Biochem Cell Biol. 2020;126:105803; Doi: 10.1016/j.biocel.2020.105803</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484451</ArticleId><ArticleId IdType="pubmed">32668330</ArticleId></ArticleIdList></Reference><Reference><Citation>Motawe ZY, Farsaei F, Abdelmaboud SS, Cuevas J, Breslin JW. Sigma-1 receptor activation-induced glycolytic ATP production and endothelial barrier enhancement. Microcirculation. 2020;27(6):e12620. doi: 10.1111/micc.12620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/micc.12620</ArticleId><ArticleId IdType="pmc">PMC7821090</ArticleId><ArticleId IdType="pubmed">32279379</ArticleId></ArticleIdList></Reference><Reference><Citation>An Y, Qi Y, Li Y, Li Z, Yang C, Jia D. Activation of the sigma-1 receptor attenuates blood&#x2013;brain barrier disruption by inhibiting amyloid deposition in Alzheimer&#x2019;s disease mice. Neurosci Lett. 2022;774:136528. doi: 10.1016/j.neulet.2022.136528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2022.136528</ArticleId><ArticleId IdType="pubmed">35157973</ArticleId></ArticleIdList></Reference><Reference><Citation>Penas C, Pascual-Font A, Mancuso R, For&#xe9;s J, Casas C, Navarro X. Sigma receptor agonist 2-(4-morpholinethyl) 1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury. J Neurotrauma. 2011;28(5):831&#x2013;840. doi: 10.1089/neu.2010.1674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2010.1674</ArticleId><ArticleId IdType="pubmed">21332255</ArticleId></ArticleIdList></Reference><Reference><Citation>Francardo V, Bez F, Wieloch T, Nissbrandt H, Ruscher K, Cenci MA. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain. 2014;137(7):1998&#x2013;2014. doi: 10.1093/brain/awu107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu107</ArticleId><ArticleId IdType="pubmed">24755275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer&#x2019;s disease: a review. 3 Biotech. 2022;12(2):55; Doi: 10.1007/s13205-022-03123-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807768</ArticleId><ArticleId IdType="pubmed">35116217</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bj&#xf6;rk-Eriksson T, Alborn A-M, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4(11):1313&#x2013;1317. doi: 10.1038/3305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/3305</ArticleId><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Borb&#xe9;ly E, Varga V, Sz&#xf6;gi T, Schuster I, Bozs&#xf3; Z, Penke B, et al. Impact of two neuronal Sigma-1 receptor modulators, PRE084 and DMT, on neurogenesis and neuroinflammation in an A&#x3b2;1&#x2013;42-injected, wild-type mouse model of AD. Int J Mol Sci. 2022;23(5):2514. doi: 10.3390/ijms23052514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052514</ArticleId><ArticleId IdType="pmc">PMC8910266</ArticleId><ArticleId IdType="pubmed">35269657</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Xu B, Zhu Y, Chen L, Sokabe M, Chen L. DHEA prevents A&#x3b2;25&#x2013;35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling. Neuropharmacol. 2010;59(4&#x2013;5):323&#x2013;333. doi: 10.1016/j.neuropharm.2010.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.02.009</ArticleId><ArticleId IdType="pubmed">20167228</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;vez-Silva HM, Cuesto G, Romero N, Brito-Armas JM, Acevedo-Arozena A, Acebes &#xc1;, et al. Pridopidine promotes synaptogenesis and reduces spatial memory deficits in the Alzheimer&#x2019;s disease APP/PS1 mouse model. Neurotherapeutics. 2022;19(5):1566&#x2013;1587. doi: 10.1007/s13311-022-01280-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01280-1</ArticleId><ArticleId IdType="pmc">PMC9606189</ArticleId><ArticleId IdType="pubmed">35917088</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzm&#xe1;n-Lenis MS, Navarro X, Casas C. Selective sigma receptor agonist 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons. Neuroscience. 2009;162(1):31&#x2013;38. doi: 10.1016/j.neuroscience.2009.03.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2009.03.067</ArticleId><ArticleId IdType="pubmed">19345724</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Oliv&#xe1;n S, Rando A, Casas C, Osta R, Navarro X. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012;9(4):814&#x2013;826. doi: 10.1007/s13311-012-0140-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-012-0140-y</ArticleId><ArticleId IdType="pmc">PMC3480575</ArticleId><ArticleId IdType="pubmed">22935988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Del Valle J, Morell M, Pall&#xe1;s M, Osta R, Navarro X. Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity? Orphanet J Rare Dis. 2014;9(1):1&#x2013;11. doi: 10.1186/1750-1172-9-78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-9-78</ArticleId><ArticleId IdType="pmc">PMC4035830</ArticleId><ArticleId IdType="pubmed">24885036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaja-Capdevila N, Hern&#xe1;ndez N, Navarro X, Herrando-Grabulosa M. Sigma-1 receptor is a pharmacological target to promote neuroprotection in the SOD1G93A ALS mice. Front Pharmacol. 2021;12:780588. doi: 10.3389/fphar.2021.780588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.780588</ArticleId><ArticleId IdType="pmc">PMC8702863</ArticleId><ArticleId IdType="pubmed">34955848</ArticleId></ArticleIdList></Reference><Reference><Citation>Peviani M, Salvaneschi E, Bontempi L, Petese A, Manzo A, Rossi D, et al. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol Dis. 2014;62:218&#x2013;232. doi: 10.1016/j.nbd.2013.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.10.010</ArticleId><ArticleId IdType="pubmed">24141020</ArticleId></ArticleIdList></Reference><Reference><Citation>Barwick SR, Siddiq MS, Wang J, Xiao H, Marshall B, Perry E, et al. Sigma 1 receptor co-localizes with NRF2 in retinal photoreceptor cells. Antioxidants. 2021;10(6):981. doi: 10.3390/antiox10060981.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10060981</ArticleId><ArticleId IdType="pmc">PMC8234060</ArticleId><ArticleId IdType="pubmed">34205384</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng TY, Hung DT, Su TP, Tsai SYA. Loss of Sigma-1 receptor chaperone promotes astrocytosis and enhances the Nrf2 antioxidant defense. Oxid Med Cell Longev. 2017;2017:4582135. doi: 10.1155/2017/4582135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/4582135</ArticleId><ArticleId IdType="pmc">PMC5573104</ArticleId><ArticleId IdType="pubmed">28883901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasbleiz C, Peyrel A, Tarot P, Sarniguet J, Crouzier L, Cubedo N, et al. Sigma-1 receptor agonist PRE-084 confers protection against TAR DNA-binding protein-43 toxicity through NRF2 signalling. Redox Biol. 2022;58:102542. doi: 10.1016/j.redox.2022.102542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2022.102542</ArticleId><ArticleId IdType="pmc">PMC9706169</ArticleId><ArticleId IdType="pubmed">36442393</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyrskyluoto A, Pulli I, T&#xf6;rnqvist K, Ho H, Korhonen L, Lindholm D. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-&#x3ba;B pathway. Cell Death Dis. 2013;4(5):e646. doi: 10.1038/cddis.2013.170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.170</ArticleId><ArticleId IdType="pmc">PMC3674377</ArticleId><ArticleId IdType="pubmed">23703391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#x2019;Shakova A, Kraskovskaya N, Gainullina A, Kukanova E, Vlasova O, Bezprozvanny I. Neuroprotective effect of &#x3c3;1-receptors on the cell model of Huntington&#x2019;s disease. Bull Exp Biol Med. 2017;164:252&#x2013;8. 10.1007/s10517-017-3968-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29177899</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, et al. Pridopidine, a clinic-ready compound, reduces 3, 4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov Disord. 2019;34(5):708&#x2013;716. doi: 10.1002/mds.27565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27565</ArticleId><ArticleId IdType="pubmed">30575996</ArticleId></ArticleIdList></Reference><Reference><Citation>Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, et al. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study. Eur J Nucl Med Mol Imaging. 2021;48(4):1103&#x2013;1115. doi: 10.1007/s00259-020-05030-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05030-3</ArticleId><ArticleId IdType="pmc">PMC8041674</ArticleId><ArticleId IdType="pubmed">32995944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahlholm K, Sijbesma JWA, Maas B, Kwizera C, Marcellino D, Ramakrishnan NK, et al. Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology. 2015;232(18):3443&#x2013;3453. doi: 10.1007/s00213-015-3997-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-015-3997-8</ArticleId><ArticleId IdType="pmc">PMC4537502</ArticleId><ArticleId IdType="pubmed">26159455</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne J, Harris KM. Do thin spines learn to be mushroom spines that remember? Curr Opin Neurobiol. 2007;17(3):381&#x2013;386. doi: 10.1016/j.conb.2007.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2007.04.009</ArticleId><ArticleId IdType="pubmed">17498943</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne JN, Harris KM. Balancing structure and function at hippocampal dendritic spines. Annu Rev Neurosci. 2008;31:47&#x2013;67. doi: 10.1146/annurev.neuro.31.060407.125646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.31.060407.125646</ArticleId><ArticleId IdType="pmc">PMC2561948</ArticleId><ArticleId IdType="pubmed">18284372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi-Takagi A, Yagishita S, Nakamura M, Shirai F, Wu YI, Loshbaugh AL, et al. Labelling and optical erasure of synaptic memory traces in the motor cortex. Nature. 2015;525(7569):333&#x2013;338. doi: 10.1038/nature15257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15257</ArticleId><ArticleId IdType="pmc">PMC4634641</ArticleId><ArticleId IdType="pubmed">26352471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu A, Gradus T, Altman T, Maimon R, Avraham NS, Geva M, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model. Cell Death Dis. 2019;10(3):210. doi: 10.1038/s41419-019-1451-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1451-2</ArticleId><ArticleId IdType="pmc">PMC6397200</ArticleId><ArticleId IdType="pubmed">30824685</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;vez-Silva HM, Mediavilla T, Giacobbo BL, Liu X, Sultan FR, Marcellino DJ. Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2022;55(5):1356&#x2013;1372. doi: 10.1111/ejn.15608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.15608</ArticleId><ArticleId IdType="pmc">PMC9305776</ArticleId><ArticleId IdType="pubmed">35080077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S-M, Wu H-E, Yasui Y, Geva M, Hayden M, Maurice T, et al. Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine. Autophagy. 2023;19(1):126&#x2013;151. doi: 10.1080/15548627.2022.2063003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2022.2063003</ArticleId><ArticleId IdType="pmc">PMC9809944</ArticleId><ArticleId IdType="pubmed">35507432</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, et al. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI insight. 2017;2:23. doi: 10.1172/jci.insight.95665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.95665</ArticleId><ArticleId IdType="pmc">PMC5752291</ArticleId><ArticleId IdType="pubmed">29212949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen KQ, Rymar VV, Sadikot AF. Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6/2 mouse model of Huntington&#x2019;s disease. Front Cell Neurosci. 2016;10:37. doi: 10.3389/fncel.2016.00037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00037</ArticleId><ArticleId IdType="pmc">PMC4783409</ArticleId><ArticleId IdType="pubmed">27013968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, et al. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol Neurodegener. 2018;13(1):25. doi: 10.1186/s13024-018-0259-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0259-3</ArticleId><ArticleId IdType="pmc">PMC5963017</ArticleId><ArticleId IdType="pubmed">29783994</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington&#x2019;s disease phenotypes in YAC128 mice. J Neurosci. 2010;30(44):14708&#x2013;14718. doi: 10.1523/JNEUROSCI.1637-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1637-10.2010</ArticleId><ArticleId IdType="pmc">PMC2989389</ArticleId><ArticleId IdType="pubmed">21048129</ArticleId></ArticleIdList></Reference><Reference><Citation>Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet. 2016;25(18):3975&#x2013;3987. doi: 10.1093/hmg/ddw238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw238</ArticleId><ArticleId IdType="pmc">PMC5291233</ArticleId><ArticleId IdType="pubmed">27466197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagasaki Y, Numakawa T, Kumamaru E, Hayashi T, Su TP, Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem. 2006;281(18):12941&#x2013;12949. doi: 10.1074/jbc.M508157200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508157200</ArticleId><ArticleId IdType="pubmed">16522641</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington Study Group HART Investigators A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington&#x2019;s disease. Mov Disord. 2013;28(10):1407&#x2013;1415. doi: 10.1002/mds.25362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25362</ArticleId><ArticleId IdType="pubmed">23450660</ArticleId></ArticleIdList></Reference><Reference><Citation>De Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, et al. Pridopidine for the treatment of motor function in patients with Huntington&#x2019;s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049&#x2013;1057. doi: 10.1016/S1474-4422(11)70233-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70233-2</ArticleId><ArticleId IdType="pubmed">22071279</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilmann R, McGarry A, Grachev ID, Savola J-M, Borowsky B, Eyal E, et al. Safety and efficacy of pridopidine in patients with Huntington&#x2019;s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18(2):165&#x2013;176. doi: 10.1016/S1474-4422(18)30391-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30391-0</ArticleId><ArticleId IdType="pubmed">30563778</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry A, Auinger P, Kieburtz K, Geva M, Mehra M, Abler V, et al. Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease. J Huntingtons Dis. 2020;9(2):173&#x2013;184. doi: 10.3233/JHD-190393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-190393</ArticleId><ArticleId IdType="pubmed">32508327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponten H, Kullingsj&#xf6; J, Sonesson C, Waters S, Waters N, Tedroff J. The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model. Eur J Pharmacol. 2013;698(1&#x2013;3):278&#x2013;285. doi: 10.1016/j.ejphar.2012.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2012.10.039</ArticleId><ArticleId IdType="pubmed">23127496</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarthing K, Prakash N, Simuni T. Clinical trial highlights &#x2013; dyskinesia. J Parkinsons Dis. 2019;9:449&#x2013;465. doi: 10.3233/JPD-199002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-199002</ArticleId><ArticleId IdType="pmc">PMC6704371</ArticleId><ArticleId IdType="pubmed">31356217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson&#x2019;s disease: a feature inherent to the treatment or the disease? Prog Neurobiol. 2009;87(1):1&#x2013;9. doi: 10.1016/j.pneurobio.2008.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2008.09.013</ArticleId><ArticleId IdType="pmc">PMC2916171</ArticleId><ArticleId IdType="pubmed">18938208</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer&#x2019;s disease: focus on rivastigmine. Ther Adv Drug Saf. 2018;9(3):171&#x2013;178. doi: 10.1177/2042098617750555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042098617750555</ArticleId><ArticleId IdType="pmc">PMC5810854</ArticleId><ArticleId IdType="pubmed">29492246</ArticleId></ArticleIdList></Reference><Reference><Citation>Terada K, Migita K, Matsushima Y, Sugimoto Y, Kamei C, Matsumoto T, et al. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PLoS ONE. 2018;13(12):e0209250. doi: 10.1371/journal.pone.0209250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0209250</ArticleId><ArticleId IdType="pmc">PMC6296549</ArticleId><ArticleId IdType="pubmed">30557385</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey-Bloom J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer&#x2019;s disease. Int J Geriatr Psyopharmacol. 1998;1:55&#x2013;65.</Citation></Reference><Reference><Citation>R&#xf6;sler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer&#x2019;s disease: international randomised controlled trial. BMJ. 1999;318(7184):633&#x2013;638. doi: 10.1136/bmj.318.7184.633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.318.7184.633</ArticleId><ArticleId IdType="pmc">PMC27767</ArticleId><ArticleId IdType="pubmed">10066203</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer&#x2019;s disease. Clin Ther. 2004;26(7):980&#x2013;990. doi: 10.1016/s0149-2918(04)90172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0149-2918(04)90172-5</ArticleId><ArticleId IdType="pubmed">15336465</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi B, Sahn JJ, Ardestani PM, Evans AK, Scott LL, Chan JZ, et al. Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer&#x2019;s disease. J Neurochem. 2017;140(4):561&#x2013;575. doi: 10.1111/jnc.13917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13917</ArticleId><ArticleId IdType="pmc">PMC5312682</ArticleId><ArticleId IdType="pubmed">27926996</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano T, Tanabe H, Kobayashi K, Kobayashi H, Nabetani A, Sakai Y, et al. Sigma-1 receptor is a molecular target for novel neuroprotectant T-817MA. Alzheimer Dement. 2015;11(7):P861. doi: 10.1016/j.jalz.2015.08.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.08.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen PTH, Kimura T, Ho SA, Tran AH, Ono T, Nishijo H. Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-&#x3b2; peptide (1&#x2013;40) in rats. Hippocampus. 2007;17(6):443&#x2013;455. doi: 10.1002/hipo.20281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.20281</ArticleId><ArticleId IdType="pubmed">17397046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Hong Nguyen PT, Ho SA, Tran AH, Ono T, Nishijo H. T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused icv with amyloid-&#x3b2; peptide. Br J Pharmacol. 2009;157(3):451&#x2013;463. doi: 10.1111/j.1476-5381.2009.00141.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2009.00141.x</ArticleId><ArticleId IdType="pmc">PMC2707991</ArticleId><ArticleId IdType="pubmed">19371351</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, et al. Safety and efficacy of edonerpic maleate for patients with mild to moderate alzheimer disease: a phase 2 randomized clinical trial. JAMA Neurol. 2019;76(11):1330&#x2013;1339. doi: 10.1001/jamaneurol.2019.1868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1868</ArticleId><ArticleId IdType="pmc">PMC6618817</ArticleId><ArticleId IdType="pubmed">31282954</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L, Porsteinsson A, Farlow M, Shimakura A, Nakagawa M, Iwakami N. The neuroprotective and neurotrophic agent T-817MA for Alzheimer&#x2019;s disease: randomized, double-blind, placebo-controlled proof-of-concept trial outcomes. Alzheimers Dement. 2013;9(4):P530&#x2013;P531. doi: 10.1016/j.jalz.2013.04.272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.04.272</ArticleId></ArticleIdList></Reference><Reference><Citation>Audronyt&#x117; E, Kaubrys G. Odor identification and discrimination as markers of early Alzheimer&#x2019;s disease. Alzheimers Dement. 2022;18:e063101. doi: 10.1002/alz.063101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.063101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudd F, Shiel A, Harris M, Bowdler P, Wood B, Tsivos D, et al. novel blood biomarkers that correlate with cognitive performance and hippocampal volumetry: potential for early diagnosis of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2019;67(3):931&#x2013;947. doi: 10.3233/JAD-180879.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180879</ArticleId><ArticleId IdType="pubmed">30689581</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto JM, Wroblewski KE, Kern DW, Schumm LP, McClintock MK. Olfactory dysfunction predicts 5-year mortality in older adults. PLoS ONE. 2014;9(10):e107541. doi: 10.1371/journal.pone.0107541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107541</ArticleId><ArticleId IdType="pmc">PMC4182669</ArticleId><ArticleId IdType="pubmed">25271633</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams DR, Kern DW, Wroblewski KE, McClintock MK, Dale W, Pinto JM. Olfactory dysfunction predicts subsequent dementia in older US adults. J Am Geriatr Soc. 2018;66(1):140&#x2013;144. doi: 10.1111/jgs.15048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15048</ArticleId><ArticleId IdType="pmc">PMC6317879</ArticleId><ArticleId IdType="pubmed">28944467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Lee J, Harrou F, Sun Y. Early detection of Parkinson&#x2019;s disease using deep learning and machine learning. IEEE Access. 2020;8:147635&#x2013;147646. doi: 10.1109/ACCESS.2020.3016062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ACCESS.2020.3016062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C-H, Wang F-C, Kuo T-Y, Huang P-W, Chen S-F, Fu L-C. Early detection of Parkinson&#x2019;s disease by neural network models. IEEE Access. 2022;10:19033&#x2013;19044. doi: 10.1109/ACCESS.2022.3150774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ACCESS.2022.3150774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>